{ "company": "Guardant Health", "ticker": "GH", "period": { "from": "2026-03-18", "to": "2026-04-17", "days": 30 }, "sentiment_breakdown": { "positive": 74, "negative": 74, "neutral": 47 }, "synthesis": { "executive_summary": "Sentiment analysis for Guardant Health (GH) from 2026-03-18 to 2026-04-17. Analyzed 195 items across FDA and news sources.", "key_findings": [], "overall_sentiment": "neutral" }, "top_positive": [ { "title": "ENTERTAINMENT GH with OLA MICHAEL on NEAT 100.9 FM 9/04/2026", "date": "2026-04-10", "source": "news", "score": 0.939 }, { "title": "Tests show $30,000 AI GPUs are terrible password crackers — RTX 5090 gaming GPU outperforms Nvidia H200 and AMD MI300X", "date": "2026-04-11", "source": "news", "score": 0.9 }, { "title": "Guardant Health gets oncology innovation accolade at Healthcare Asia Medtech Awards 2026", "date": "2026-04-01", "source": "alpha_vantage", "score": 0.881 }, { "title": "Into the Wood Chipper", "date": "2026-04-14", "source": "news", "score": 0.852 }, { "title": "Molecular Tumor Board Solutions Market Outlook 2026-2030 & 2035 with Competitor Market Share Data", "date": "2026-04-07", "source": "news", "score": 0.832 }, { "title": "5 popular OpenClaw integrations that will level up your productivity", "date": "2026-04-02", "source": "news", "score": 0.822 }, { "title": "Testing FRRouting Pull Requests with netlab", "date": "2026-04-16", "source": "news", "score": 0.807 }, { "title": "Panasonic 25th anniversary: Chinese socials bet on the lunch of many new MFT cameras!", "date": "2026-04-14", "source": "news", "score": 0.806 }, { "title": "Effects of a native avian predator (weka; Gallirallus australis) and colony density on breeding success of a burrow-nesting seabird (tītī; Ardenna grisea)", "date": "2026-04-02", "source": "news", "score": 0.802 }, { "title": "Show HN: Infer – Pipe friendly Agent Harness with one tool: Bash", "date": "2026-04-08", "source": "news", "score": 0.796 } ], "top_negative": [ { "title": "Loss of luminal lineage drives resistance to next-generation ERα antagonists in pretreated ER(+) HER2(-) locally-advanced or metastatic breast cancer.", "date": "2026 Apr 1", "source": "pubmed", "score": -1.0 }, { "title": "Teacher, two farmers arraigned over alleged criminal activities in Nkwanta", "date": "2026-04-10", "source": "news", "score": -0.902 }, { "title": "Consensus definition of stage III non-small-cell lung cancer technical resectability to standardise inclusion criteria for clinical trials: a multisocietal EORTC-Lung Cancer Group collaboration.", "date": "2026 Mar 2", "source": "pubmed", "score": -0.869 }, { "title": "Companion Diagnostics Market Size is Projected to Hit USD 26.38 Billion by 2035 – SNS Insider", "date": "2026-04-13", "source": "news", "score": -0.869 }, { "title": "The End of Eleventy", "date": "2026-04-12", "source": "news", "score": -0.857 }, { "title": "Global Noninvasive Cancer Diagnostics Market to Reach $165.2 Billion by 2030 as Liquid Biopsy, AI-Enabled Screening and Multi-Cancer Detection Tests Transform Oncology", "date": "2026-04-09", "source": "news", "score": -0.823 }, { "title": "Utility of Circulating Tumor DNA-Based Liquid Biopsies in Patients with Cancer Receiving Immunotherapy.", "date": "2026-04-17", "source": "pubmed", "score": -0.791 }, { "title": "Colorectal Cancer and Mortality Risk Among Older Adults With vs Without Adenoma on Prior Colonoscopy.", "date": "2026 Apr 9", "source": "pubmed", "score": -0.758 }, { "title": "Show HN: BAREmail ʕ·ᴥ·ʔ – minimalist Gmail client for bad WiFi", "date": "2026-04-08", "source": "news", "score": -0.758 }, { "title": "Dispatch Rider Jailed 10 Years for Robbing Diplomat’s Secretary", "date": "2026-04-03", "source": "news", "score": -0.727 } ], "raw_data": { "total_items": 195, "items": [ { "source": "alpha_vantage", "title": "Guardant Health (GH) director sells 116 shares after RSU conversion", "url": "https://www.stocktitan.net/sec-filings/GH/form-4-guardant-health-inc-insider-trading-activity-f6962445edc3.html", "date": "2026-04-17", "summary": "Guardant Health Director Tariq Musa sold 116 shares of common stock at $84.83 per share on April 16, 2026, after exercising 250 Restricted Stock Units (RSUs) on April 15, 2026. Following these transactions, Musa directly holds 8,528 shares of Common Stock and 2,749 RSUs. The RSU award, granted on March 6, 2023, has a four-year vesting schedule.", "sentiment_score": -0.185171, "sentiment_label": "Somewhat-Bearish", "relevance_score": 1.0, "sentiment": { "label": "positive", "score": 0.296, "confidence": 0.3 } }, { "source": "alpha_vantage", "title": "Guardant Health to Report First Quarter 2026 Financial Results on May 7, 2026", "url": "https://www.joplinglobe.com/region/national_business/guardant-health-to-report-first-quarter-2026-financial-results-on-may-7-2026/article_7800a306-e5e9-5b11-a639-6535d89f5ca8.html", "date": "2026-04-16", "summary": "Guardant Health, Inc. (Nasdaq: GH) announced it will release its first quarter 2026 financial results after market close on Thursday, May 7, 2026. The company will also host a conference call and webcast to discuss these results, which will be accessible on its website. Guardant Health focuses on precision oncology, aiming to improve patient care and accelerate cancer therapies through advanced blood and tissue tests, real-world data, and AI analytics.", "sentiment_score": 0.016623, "sentiment_label": "Neutral", "relevance_score": 1.0, "sentiment": { "label": "neutral", "score": 0.0, "confidence": 0.0 } }, { "source": "alpha_vantage", "title": "9,840-share Form 144 sale by Guardant Health (NASDAQ: GH)", "url": "https://www.stocktitan.net/sec-filings/GH/144-guardant-health-inc-sec-filing-12610e95a18b.html", "date": "2026-04-16", "summary": "Guardant Health (NASDAQ: GH) reported a Form 144 notice indicating a proposed sale of 9,840 common shares through Charles Schwab with a filing date of April 16, 2026. The filing also mentions a restricted stock lapse on February 15, 2026, and a previous sale of 348 shares by Musa Tariq on March 18, 2026. This SEC disclosure provides routine details of planned or recent transactions, with execution details to follow if the sale occurs.", "sentiment_score": 0.030678, "sentiment_label": "Neutral", "relevance_score": 0.326858, "sentiment": { "label": "neutral", "score": 0.0, "confidence": 0.0 } }, { "source": "alpha_vantage", "title": "Piper Sandler Maintains Guardant Health(GH.US) With Buy Rating, Maintains Target Price $130", "url": "https://www.moomoo.com/news/post/68415561/piper-sandler-maintains-guardant-health-ghus-with-buy-rating-maintains", "date": "2026-04-16", "summary": "Piper Sandler has reiterated its Buy rating for Guardant Health (GH.US) and maintained its target price at $130. This analyst action suggests continued confidence in the company's prospects.", "sentiment_score": 0.404068, "sentiment_label": "Bullish", "relevance_score": 1.0, "sentiment": { "label": "neutral", "score": 0.0, "confidence": 0.0 } }, { "source": "alpha_vantage", "title": "Piper Sandler reiterates Guardant Health stock rating on ctDNA data By Investing.com", "url": "https://ca.investing.com/news/stock-market-news/piper-sandler-reiterates-guardant-health-stock-rating-on-ctdna-data-93CH-4568927", "date": "2026-04-16", "summary": "Piper Sandler has reiterated an Overweight rating and a $130.00 price target for Guardant Health (NASDAQ:GH), citing strong clinical trial data supporting serial ctDNA testing in cancer treatment. The firm highlights data from Natera’s IMvigor011 and SERENA-6 trials, which demonstrated significant survival benefits and therapy optimization for patients using ctDNA testing. Despite the stock appearing overvalued by InvestingPro analysis, Wall Street analysts generally maintain a bullish outlook b", "sentiment_score": 0.447713, "sentiment_label": "Bullish", "relevance_score": 1.0, "sentiment": { "label": "neutral", "score": 0.0, "confidence": 0.0 } }, { "source": "alpha_vantage", "title": "Guardant Health (GH) Valuation Check After Short Term Share Price Volatility", "url": "https://simplywall.st/stocks/us/healthcare/nasdaq-gh/guardant-health/news/guardant-health-gh-valuation-check-after-short-term-share-pr", "date": "2026-04-16", "summary": "Guardant Health (GH) has experienced recent stock volatility, with short-term declines despite significant one-year gains. The company is considered undervalued by some, trading at a 51% discount to analyst targets and intrinsic value, driven by expected growth in blood-based cancer diagnostics. However, a high P/S ratio compared to industry averages suggests potential valuation risk, especially given the company is still loss-making.", "sentiment_score": 0.311755, "sentiment_label": "Somewhat-Bullish", "relevance_score": 1.0, "sentiment": { "label": "positive", "score": 0.296, "confidence": 0.3 } }, { "source": "alpha_vantage", "title": "Guardant Health: As April marks National Cancer Prevention and Early Detection Month, FDA-approved blood test for colorectal cancer screening makes it easier to screen in Wisconsin", "url": "https://www.wisbusiness.com/2026/guardant-health-as-april-marks-national-cancer-prevention-and-early-detection-month-fda-approved-blood-test-for-colorectal-cancer-screening-makes-it-easier-to-screen-in-wisconsin/", "date": "2026-04-16", "summary": "Guardant Health is expanding access to its FDA-approved Shield™ blood test for colorectal cancer screening in Wisconsin, aligning with National Cancer Prevention and Early Detection Month. This innovative test offers an easier alternative to traditional methods, aiming to close the state's colorectal cancer screening gap, where CRC is the third leading cause of cancer-related deaths. The company has also launched \"Shield Across America\" to raise awareness nationwide, emphasizing that early detec", "sentiment_score": 0.458943, "sentiment_label": "Bullish", "relevance_score": 1.0, "sentiment": { "label": "negative", "score": -0.591, "confidence": 0.59 } }, { "source": "alpha_vantage", "title": "Guardant Health, Inc. $GH Position Cut by Massachusetts Financial Services Co. MA", "url": "https://www.marketbeat.com/instant-alerts/filing-guardant-health-inc-gh-position-cut-by-massachusetts-financial-services-co-ma-2026-04-16/", "date": "2026-04-16", "summary": "Massachusetts Financial Services Co. significantly reduced its stake in Guardant Health (NASDAQ:GH) by 21.7% in Q4 2025, selling 65,841 shares, though it still holds over $24 million worth of the stock. Despite this, institutional ownership remains high at 92.6%, with other firms like Alyeska and Allspring initiating new, substantial positions. Analysts are largely bullish on Guardant Health, with 20 Buy ratings and an average target price of $125.20, after the company beat revenue estimates in ", "sentiment_score": 0.049743, "sentiment_label": "Neutral", "relevance_score": 1.0, "sentiment": { "label": "negative", "score": -0.273, "confidence": 0.27 } }, { "source": "alpha_vantage", "title": "Will Guardant Health (GH) Report Negative Earnings Next Week? What You Should Know", "url": "https://www.easternprogress.com/will-guardant-health-gh-report-negative-earnings-next-week-what-you-should-know/article_386362af-47b6-5115-99dc-06a7977437cb.html", "date": "2026-04-16", "summary": "Guardant Health (GH) is expected to report a year-over-year increase in earnings on higher revenues for the quarter ended December 2025. While analysts anticipate a quarterly loss of $0.42 per share, representing a 32.3% improvement, the Zacks Earnings ESP suggests analysts have recently become more bearish, making it difficult to conclusively predict an earnings beat. Investors are advised to consider the company's Zacks Rank #3 and other factors in addition to the Earnings ESP for their invest", "sentiment_score": 0.041159, "sentiment_label": "Neutral", "relevance_score": 1.0, "sentiment": { "label": "negative", "score": -0.572, "confidence": 0.57 } }, { "source": "alpha_vantage", "title": "Barclays Maintains Guardant Health(GH.US) With Buy Rating, Cuts Target Price to $115", "url": "https://www.moomoo.com/news/post/68286288/barclays-maintains-guardant-health-ghus-with-buy-rating-cuts-target", "date": "2026-04-15", "summary": "Barclays has reiterated its Buy rating for Guardant Health (GH.US) but has reduced its target price to $115 from the previous $120. This adjustment in the price target reflects a revised outlook from the analyst while maintaining a positive sentiment towards the company's stock.", "sentiment_score": 0.114752, "sentiment_label": "Neutral", "relevance_score": 1.0, "sentiment": { "label": "negative", "score": -0.296, "confidence": 0.3 } }, { "source": "alpha_vantage", "title": "Mizuho Securities Maintains Guardant Health(GH.US) With Buy Rating, Maintains Target Price $135", "url": "https://www.moomoo.com/news/post/68237052/mizuho-securities-maintains-guardant-health-ghus-with-buy-rating-maintains", "date": "2026-04-13", "summary": "Mizuho Securities has reiterated its Buy rating on Guardant Health (GH.US) and maintained its price target at $135. This continued positive outlook suggests the firm believes Guardant Health's stock has significant upside potential based on their analysis.", "sentiment_score": 0.429776, "sentiment_label": "Bullish", "relevance_score": 1.0, "sentiment": { "label": "positive", "score": 0.296, "confidence": 0.3 } }, { "source": "alpha_vantage", "title": "TD Cowen cuts Guardant Health stock price target on valuation By Investing.com", "url": "https://za.investing.com/news/stock-market-news/td-cowen-cuts-guardant-health-stock-price-target-on-valuation-93CH-4208905", "date": "2026-04-13", "summary": "TD Cowen has reduced its price target for Guardant Health (NASDAQ:GH) shares from $135 to $120, while maintaining a Buy rating, citing valuation concerns due to higher interest rates and a volatile macroeconomic environment. Despite the stock trading at $79.55, suggesting an upside to the new target, InvestingPro analysis indicates it might be currently overvalued. The firm anticipates first-quarter sales of $306 million and projects key catalysts such as upcoming FDA decisions for G360 and Shie", "sentiment_score": 0.078997, "sentiment_label": "Neutral", "relevance_score": 1.0, "sentiment": { "label": "negative", "score": -0.296, "confidence": 0.3 } }, { "source": "alpha_vantage", "title": "TD Cowen cuts Guardant Health stock price target on valuation", "url": "https://www.investing.com/news/analyst-ratings/td-cowen-cuts-guardant-health-stock-price-target-on-valuation-93CH-4610620", "date": "2026-04-13", "summary": "TD Cowen has reduced its price target for Guardant Health (NASDAQ:GH) shares from $135 to $120, maintaining a Buy rating despite the stock trading significantly below the new target. The revision is based on a lower enterprise value to next-twelve-months sales multiple, influenced by higher interest rates and a volatile macroeconomic environment. The firm anticipates a first-quarter sales beat for Guardant Health but also notes that nine analysts have revised earnings downwards for the upcoming ", "sentiment_score": -0.183424, "sentiment_label": "Somewhat-Bearish", "relevance_score": 1.0, "sentiment": { "label": "negative", "score": -0.296, "confidence": 0.3 } }, { "source": "alpha_vantage", "title": "Cloudflare, ServiceNow, And Guardant Health Are Among Top 10 Large-Cap Losers Last Week (April 6-April 10", "url": "https://www.benzinga.com/markets/equities/26/04/51770668/cloudflare-servicenow-and-guardant-health-are-among-top-10-large-cap-losers-last-week-april-6-april-10-are-the-others-in-your-portfolio", "date": "2026-04-12", "summary": "The article reports on the top ten large-cap stock losers from April 6-10, with Cloudflare, ServiceNow, and Guardant Health being notable mentions. Weak macro signals, rising AI competition, and analyst downgrades contributed to a broad sell-off across software and cloud companies. Despite some companies making product launches or strategic moves, their stock prices experienced significant weekly declines.", "sentiment_score": -0.411753, "sentiment_label": "Bearish", "relevance_score": 1.0, "sentiment": { "label": "negative", "score": -0.382, "confidence": 0.38 } }, { "source": "alpha_vantage", "title": "Guardant Health Surges to $510 Million in Trading Volume as Insiders and Institutional Investors Dispute Over $81 Share Price", "url": "https://www.bitget.com/amp/news/detail/12560605357492", "date": "2026-04-10", "summary": "Guardant Health (NASDAQ: GH) experienced a significant 9.83% drop in share price to $81.11, yet saw a massive surge in trading volume reaching $510 million. This volatility is attributed to substantial institutional selling and insider transactions, despite the company exceeding revenue forecasts in its latest earnings report. A notable divergence exists between insider selling and strong analyst \"Buy\" ratings, with price targets averaging $125.95, reflecting a complex and disputed valuation.", "sentiment_score": -0.216174, "sentiment_label": "Somewhat-Bearish", "relevance_score": 1.0, "sentiment": { "label": "negative", "score": -0.128, "confidence": 0.13 } }, { "source": "alpha_vantage", "title": "Guardant Health Inc (GH) Stock Price Down 4.62% on Apr 9", "url": "https://www.gurufocus.com/news/8785466/guardant-health-inc-gh-stock-price-down-462-on-apr-9?mobile=true", "date": "2026-04-09", "summary": "Guardant Health Inc (GH) stock fell 4.62% on April 9th, reaching an intraday low of $88.22 before closing slightly higher at $88.61. This places the stock significantly above its 52-week low but still below its 52-week high. Wall Street analysts provide an average target price of $129.67, suggesting a 46.35% upside, with an \"Outperform\" consensus, while GuruFocus' estimated GF Value indicates a potential downside of 22.65% from the current price.", "sentiment_score": -0.389598, "sentiment_label": "Bearish", "relevance_score": 1.0, "sentiment": { "label": "neutral", "score": 0.0, "confidence": 0.0 } }, { "source": "alpha_vantage", "title": "Guardant Health (Nasdaq:GH) - Stock Analysis", "url": "https://simplywall.st/stocks/us/healthcare/nasdaq-gh/guardant-health", "date": "2026-04-09", "summary": "Guardant Health (Nasdaq:GH) is a precision oncology company currently trading at US$78.60, which is 54.8% below its estimated fair value of US$129.73 according to analysts, making it 39.4% undervalued. The company faces risks such as negative shareholder equity and current unprofitability, with revenue forecast to grow by 20.8% annually. Despite recent insider selling, strong demand for blood-based cancer diagnostics and strategic expansions are expected to drive future growth and improve its pa", "sentiment_score": 0.027179, "sentiment_label": "Neutral", "relevance_score": 0.312584, "sentiment": { "label": "neutral", "score": 0.0, "confidence": 0.0 } }, { "source": "alpha_vantage", "title": "Guardant Health (GH) Chief People Officer sells 3,832 shares in open market", "url": "https://www.stocktitan.net/sec-filings/GH/form-4-guardant-health-inc-insider-trading-activity-32117b2b4a92.html", "date": "2026-04-08", "summary": "Guardant Health's Chief People Officer, Terilyn J. Monroe, sold 3,832 shares of common stock at $92.68 per share in an open-market transaction. Following this sale, Monroe still directly holds 20,990 shares of the company. This insider transaction was reported in a Form 4 filing, indicating a moderate impact and negative sentiment.", "sentiment_score": -0.206334, "sentiment_label": "Somewhat-Bearish", "relevance_score": 1.0, "sentiment": { "label": "positive", "score": 0.296, "confidence": 0.3 } }, { "source": "alpha_vantage", "title": "Citi Maintains Guardant Health(GH.US) With Buy Rating, Maintains Target Price $150", "url": "https://www.moomoo.com/news/post/67968522/citi-maintains-guardant-health-ghus-with-buy-rating-maintains-target", "date": "2026-04-08", "summary": "Citi has reiterated its Buy rating for Guardant Health (GH.US), maintaining a target price of $150. This continued endorsement suggests confidence in the company's future performance and valuation. The specific reasons for Citi's reiterated stance were not detailed in the provided content.", "sentiment_score": 0.48426, "sentiment_label": "Bullish", "relevance_score": 0.964043, "sentiment": { "label": "neutral", "score": 0.0, "confidence": 0.0 } }, { "source": "alpha_vantage", "title": "Should Guardant Health’s (GH) Role in ENHERTU’s Japan Approval Require Action From Investors?", "url": "https://simplywall.st/stocks/us/healthcare/nasdaq-gh/guardant-health/news/should-guardant-healths-gh-role-in-enhertus-japan-approval-r/amp", "date": "2026-04-08", "summary": "Guardant Health's InfinityAI platform was instrumental in the Japanese approval of Daiichi Sankyo's ENHERTU, a development that could enhance Guardant's standing in biopharma and data partnerships. While this strengthens the investment narrative around its AI and real-world evidence capabilities, the company still faces significant challenges, including ongoing losses, high spending, and potential future dilution. Investors are encouraged to weigh this positive news against the risks of negative", "sentiment_score": 0.149023, "sentiment_label": "Neutral", "relevance_score": 0.999309, "sentiment": { "label": "positive", "score": 0.477, "confidence": 0.48 } }, { "source": "alpha_vantage", "title": "Should Guardant Health’s (GH) Role in ENHERTU’s Japan Approval Require Action From Investors?", "url": "https://simplywall.st/stocks/us/healthcare/nasdaq-gh/guardant-health/news/should-guardant-healths-gh-role-in-enhertus-japan-approval-r", "date": "2026-04-08", "summary": "Guardant Health's InfinityAI platform was instrumental in obtaining Japan's approval for Daiichi Sankyo's ENHERTU, showcasing its potential in leveraging clinicogenomic data and AI for regulatory assessments. While this strengthens Guardant's position in the biopharma and data sectors, the article emphasizes that the core investment risks remain centered on high spending, negative free cash flow, and potential future dilution. Investors should consider the company's long-term financial health an", "sentiment_score": 0.184722, "sentiment_label": "Somewhat-Bullish", "relevance_score": 0.988745, "sentiment": { "label": "positive", "score": 0.477, "confidence": 0.48 } }, { "source": "alpha_vantage", "title": "Insider Sell: Terilyn Monroe Sells Shares of Guardant Health Inc (GH)", "url": "https://www.gurufocus.com/news/8780017/insider-sell-terilyn-monroe-sells-shares-of-guardant-health-inc-gh", "date": "2026-04-08", "summary": "Terilyn Monroe, Chief People Officer at Guardant Health Inc (GH), sold 3,832 shares of the company on April 6, 2026. This transaction follows a pattern of 45 insider sells and no buys over the past year. Guardant Health Inc's stock is currently trading at $92.68, which is significantly overvalued compared to its GF Value of $53.19.", "sentiment_score": -0.420356, "sentiment_label": "Bearish", "relevance_score": 1.0, "sentiment": { "label": "positive", "score": 0.296, "confidence": 0.3 } }, { "source": "alpha_vantage", "title": "Guardant Health Insider Sells $355K in Shares", "url": "https://nationaltoday.com/us/ca/redwood-city/news/2026/04/07/guardant-health-insider-sells-355k-in-shares/", "date": "2026-04-07", "summary": "A Guardant Health insider, Terilyn Monroe, recently sold 3,832 shares of the company's stock for over $355,000. This transaction, executed under a pre-arranged trading plan, has raised questions about the company's future prospects. While the sale could signal potential concerns, the use of a Rule 10b5-1 plan aims to prevent allegations of insider trading.", "sentiment_score": -0.289494, "sentiment_label": "Somewhat-Bearish", "relevance_score": 1.0, "sentiment": { "label": "positive", "score": 0.296, "confidence": 0.3 } }, { "source": "alpha_vantage", "title": "Guardant Health (GH) chief people officer sells $355k in stock", "url": "https://www.investing.com/news/insider-trading-news/guardant-health-gh-chief-people-officer-sells-355k-in-stock-93CH-4601762", "date": "2026-04-07", "summary": "Guardant Health's Chief People Officer, Terilyn J. Monroe, sold 3,832 shares of common stock for approximately $355,149. This transaction occurred after a significant 123% stock gain over the past year, though the stock is currently considered overvalued by InvestingPro analysis. The article also touches on recent company news, including strong Q4 2025 results and positive analyst ratings.", "sentiment_score": 0.134034, "sentiment_label": "Neutral", "relevance_score": 1.0, "sentiment": { "label": "neutral", "score": 0.0, "confidence": 0.0 } }, { "source": "alpha_vantage", "title": "Canaccord reiterates Guardant Health stock rating on cancer test growth", "url": "https://www.investing.com/news/analyst-ratings/canaccord-reiterates-guardant-health-stock-rating-on-cancer-test-growth-93CH-4600161", "date": "2026-04-07", "summary": "Canaccord Genuity reiterated a Buy rating and $135 price target for Guardant Health (NASDAQ:GH), citing the strong performance and growth potential of the company's cancer screening initiatives, particularly the Shield test. Despite the stock's significant return over the past year, InvestingPro analysis indicates it trades above its fair value. Guardant Health's Shield test has exceeded historical benchmarks for screening and diagnostic test launches, with expectations of 150% year-over-year te", "sentiment_score": 0.743125, "sentiment_label": "Bullish", "relevance_score": 0.997376, "sentiment": { "label": "negative", "score": -0.421, "confidence": 0.42 } }, { "source": "alpha_vantage", "title": "Guardant Health, Organon, Fortrea, QuidelOrtho, and Charles River Laboratories Stocks Trade Down, What You Need To Know", "url": "https://www.tradingview.com/news/stockstory:39a9d653b094b:0-guardant-health-organon-fortrea-quidelortho-and-charles-river-laboratories-stocks-trade-down-what-you-need-to-know/", "date": "2026-04-06", "summary": "Shares of several health-related companies, including Guardant Health, Organon, Fortrea, QuidelOrtho, and Charles River Laboratories, experienced declines after a proposed 2027 federal budget revealed significant spending cuts for key health agencies like the Department of Health and Human Services and the National Institutes of Health. While Congress is unlikely to approve the full extent of the cuts, the proposal introduced uncertainty for the sector, causing immediate stock drops. QuidelOrtho", "sentiment_score": -0.337664, "sentiment_label": "Somewhat-Bearish", "relevance_score": 1.0, "sentiment": { "label": "neutral", "score": 0.0, "confidence": 0.0 } }, { "source": "alpha_vantage", "title": "[144] Guardant Health, Inc. SEC Filing", "url": "https://www.stocktitan.net/sec-filings/GH/144-guardant-health-inc-sec-filing-5a5dabd6720a.html", "date": "2026-04-06", "summary": "Guardant Health, Inc. (GH) has filed a Form 144 with the SEC, indicating proposed sales of common stock. This filing details a future sale of 3,832 shares through Charles Schwab & Co. on April 1, 2026, stemming from a restricted stock lapse. It also discloses two past sales by Terilyn J. Monroe on January 7, 2026, and January 21, 2026, totaling 18,602 shares.", "sentiment_score": 0.001283, "sentiment_label": "Neutral", "relevance_score": 1.0, "sentiment": { "label": "neutral", "score": 0.0, "confidence": 0.0 } }, { "source": "alpha_vantage", "title": "Guardant Health, Inc. $GH is Capricorn Fund Managers Ltd's 6th Largest Position", "url": "https://www.marketbeat.com/instant-alerts/filing-guardant-health-inc-gh-is-capricorn-fund-managers-ltds-6th-largest-position-2026-04-06/", "date": "2026-04-06", "summary": "Capricorn Fund Managers Ltd significantly increased its stake in Guardant Health (GH) by 197.8% in Q4, making it their 6th largest holding. Despite missing EPS estimates, Guardant Health's Q4 revenue beat expectations, leading several analysts to raise their price targets. The stock has a \"Moderate Buy\" consensus rating, high institutional ownership, but also saw insider selling.", "sentiment_score": 0.287722, "sentiment_label": "Somewhat-Bullish", "relevance_score": 1.0, "sentiment": { "label": "neutral", "score": 0.0, "confidence": 0.0 } }, { "source": "alpha_vantage", "title": "Guardant Health (GH) Valuation After Japan ENHERTU Approval Backed By InfinityAI Real World Evidence", "url": "https://simplywall.st/stocks/us/healthcare/nasdaq-gh/guardant-health/news/guardant-health-gh-valuation-after-japan-enhertu-approval-ba", "date": "2026-04-04", "summary": "Guardant Health (GH) is in focus after Japan approved ENHERTU for certain HER2 positive cancers, partly supported by Guardant's InfinityAI platform. Despite a 131.22% one-year return, the stock has seen a recent decline, prompting questions about its valuation. While a narrative suggests a 28.2% undervaluation with a fair value of $130.64 due to AI integration and expanded clinical applications, a sales multiple analysis indicates the stock might appear rich compared to the broader healthcare se", "sentiment_score": 0.333805, "sentiment_label": "Somewhat-Bullish", "relevance_score": 1.0, "sentiment": { "label": "positive", "score": 0.494, "confidence": 0.49 } }, { "source": "alpha_vantage", "title": "Guardant Health (GH) CPO gains stock from RSU vesting and tax withholding", "url": "https://www.stocktitan.net/sec-filings/GH/form-4-guardant-health-inc-insider-trading-activity-56ee3da8ffc2.html", "date": "2026-04-03", "summary": "Guardant Health's Chief People Officer, Terilyn J. Monroe, received 8,019 shares of common stock on April 1, 2026, due to the vesting of restricted stock units. Subsequently, 4,187 shares were withheld by the company at $91.15 per share to cover tax obligations. After these transactions, Monroe directly holds 24,822 shares of Guardant Health common stock, reflecting routine equity compensation rather than open-market trading.", "sentiment_score": 0.004723, "sentiment_label": "Neutral", "relevance_score": 1.0, "sentiment": { "label": "positive", "score": 0.34, "confidence": 0.34 } }, { "source": "alpha_vantage", "title": "Guardant Health (GH) CMO nets shares as RSUs vest and taxes withheld", "url": "https://www.stocktitan.net/sec-filings/GH/form-4-guardant-health-inc-insider-trading-activity-962fc1dbb93d.html", "date": "2026-04-02", "summary": "Guardant Health's Chief Medical Officer, Craig Eagle, acquired 11,400 shares of common stock through the vesting of Restricted Stock Units (RSUs) on April 1, 2026. As part of this process, 5,779 shares were withheld by the company to cover tax obligations. Following these transactions, Eagle directly holds 72,001 shares of Guardant Health common stock.", "sentiment_score": 0.008754, "sentiment_label": "Neutral", "relevance_score": 1.0, "sentiment": { "label": "positive", "score": 0.296, "confidence": 0.3 } }, { "source": "alpha_vantage", "title": "Guardant Health (GH) co-CEO reports RSU vesting, tax-share withholdings and over 2.1M shares held", "url": "https://www.stocktitan.net/sec-filings/GH/form-4-guardant-health-inc-insider-trading-activity-87afe3f0262c.html", "date": "2026-04-02", "summary": "Guardant Health's co-CEO, Helmy Eltoukhy, reported routine equity compensation activity involving Restricted Stock Units (RSUs) that vested on March 31 and April 1, 2026. These transactions resulted in the conversion of tens of thousands of RSUs into common stock, with shares withheld by the company to cover tax obligations. Following these events, Eltoukhy, through a revocable trust, holds over 2.1 million shares of common stock, in addition to directly holding 68,011 restricted stock units.", "sentiment_score": 0.028026, "sentiment_label": "Neutral", "relevance_score": 1.0, "sentiment": { "label": "positive", "score": 0.296, "confidence": 0.3 } }, { "source": "alpha_vantage", "title": "11,213 Guardant Health (GH) RSUs vest; 4,750 shares withheld for tax", "url": "https://www.stocktitan.net/sec-filings/GH/form-4-guardant-health-inc-insider-trading-activity-7025cfabc0b9.html", "date": "2026-04-02", "summary": "Guardant Health's Chief Commercial Officer, Chris Freeman, had 11,213 Restricted Stock Units (RSUs) vest on April 1, 2026. To cover tax obligations, 4,750 shares were withheld by the company at a price of $91.15 per share. Following these transactions, Freeman directly held 60,034 shares of Guardant Health common stock.", "sentiment_score": 0.011001, "sentiment_label": "Neutral", "relevance_score": 0.971883, "sentiment": { "label": "positive", "score": 0.296, "confidence": 0.3 } }, { "source": "alpha_vantage", "title": "SWS Partners Has $7.89 Million Holdings in Guardant Health, Inc. $GH", "url": "https://www.marketbeat.com/instant-alerts/filing-sws-partners-has-789-million-holdings-in-guardant-health-inc-gh-2026-04-02/", "date": "2026-04-02", "summary": "SWS Partners reduced its stake in Guardant Health (NASDAQ:GH) by 18.3% in the fourth quarter, holding 77,209 shares valued at $7.89 million, representing 1.5% of its portfolio. Guardant Health reported Q4 EPS of -$0.50, missing estimates, but revenue increased by 39.4% to $281.3 million. Analysts have a \"Moderate Buy\" consensus rating with an average target price of $125.95, despite recent insider selling totaling $2.51 million.", "sentiment_score": 0.05928, "sentiment_label": "Neutral", "relevance_score": 0.994973, "sentiment": { "label": "neutral", "score": 0.0, "confidence": 0.0 } }, { "source": "alpha_vantage", "title": "Allspring Global Investments Holdings LLC Reduces Stock Holdings in Guardant Health, Inc. $GH", "url": "https://www.marketbeat.com/instant-alerts/filing-allspring-global-investments-holdings-llc-reduces-stock-holdings-in-guardant-health-inc-gh-2026-04-02/", "date": "2026-04-02", "summary": "Allspring Global Investments Holdings LLC significantly reduced its stake in Guardant Health, Inc. (NASDAQ:GH) by 1.9% in the fourth quarter, selling 12,256 shares and now owning 618,599 shares valued at $62.94 million. Insider transactions also show sales of 23,250 shares totaling $2.51 million in the last 90 days. Despite these reductions, analysts maintain a \"Moderate Buy\" rating with an average price target of $125.95 for Guardant Health, a precision oncology company.", "sentiment_score": 0.130749, "sentiment_label": "Neutral", "relevance_score": 1.0, "sentiment": { "label": "neutral", "score": 0.0, "confidence": 0.0 } }, { "source": "alpha_vantage", "title": "Guardant Health Stock Rises on Japan Regulatory News for Daiichi Sankyo Drug - News and Statistics", "url": "https://www.indexbox.io/blog/guardant-health-stock-gains-on-japan-drug-approval-using-infinityai-data/", "date": "2026-04-02", "summary": "Guardant Health's stock saw a significant increase following the approval of a cancer drug by Daiichi Sankyo in Japan, which utilized real-world evidence from Guardant's InfinityAI platform. This event highlights the growing role of AI and real-world data in regulatory decisions for new treatments, despite the historical volatility of Guardant Health's stock. The article also includes extensive information about an antisera industry report for Japan, unrelated to the main news.", "sentiment_score": 0.310821, "sentiment_label": "Somewhat-Bullish", "relevance_score": 1.0, "sentiment": { "label": "neutral", "score": 0.0, "confidence": 0.0 } }, { "source": "alpha_vantage", "title": "Guardant Health (NasdaqGS:GH) Stock Forecast & Analyst Predictions", "url": "https://simplywall.st/stocks/us/healthcare/nasdaq-gh/guardant-health/future", "date": "2026-04-02", "summary": "Guardant Health (NasdaqGS:GH) is forecasted to experience significant growth, with earnings projected to increase by 55.1% and revenue by 20.9% annually. Despite being unprofitable for the next three years, its revenue growth is expected to outpace the US market. Analysts have also recently increased its price target, signaling positive sentiment for the company's future performance.", "sentiment_score": 0.408903, "sentiment_label": "Bullish", "relevance_score": 1.0, "sentiment": { "label": "neutral", "score": 0.0, "confidence": 0.0 } }, { "source": "alpha_vantage", "title": "Director at Guardant Health (GH) acquires 155 shares via RSUs", "url": "https://www.stocktitan.net/sec-filings/GH/form-4-guardant-health-inc-insider-trading-activity-0a86624789a6.html", "date": "2026-04-01", "summary": "Guardant Health director Steve E. Krognes acquired 155 shares of Common Stock by exercising Restricted Stock Units. This transaction on March 31, 2026, was a routine equity-compensation event at an exercise price of $0.00 per share. Following this, Krognes' direct holdings in Common Stock increased to 19,208 shares, and he retains 463 Restricted Stock Units.", "sentiment_score": 0.011169, "sentiment_label": "Neutral", "relevance_score": 0.306013, "sentiment": { "label": "positive", "score": 0.296, "confidence": 0.3 } }, { "source": "alpha_vantage", "title": "Guardant Health gets oncology innovation accolade at Healthcare Asia Medtech Awards 2026", "url": "https://mugglehead.com/guardant-health-gets-oncology-innovation-accolade-at-healthcare-asia-medtech-awards-2026/", "date": "2026-04-01", "summary": "Guardant Health Inc. (NASDAQ: GH) (FRA: 5GH) received the Oncology Product Innovation of the Year award at the Healthcare Asia Medtech Awards 2026 for its Shield multi-cancer detection test. The award comes shortly after Guardant launched Shield in Hong Kong, Singapore, and the Philippines, partnering with Manulife to offer the test to insurance customers. The Shield test, a methylation-based blood test, screens for 10 common cancers with high specificity, improving early detection and patient o", "sentiment_score": 0.404685, "sentiment_label": "Bullish", "relevance_score": 1.0, "sentiment": { "label": "positive", "score": 0.881, "confidence": 0.88 } }, { "source": "alpha_vantage", "title": "Guardant Health (GH) and Verana Health Announces New Partnership", "url": "https://www.insidermonkey.com/blog/guardant-health-gh-and-verana-health-announces-new-partnership-1727963/?amp=1", "date": "2026-03-31", "summary": "Guardant Health (NASDAQ:GH) and Verana Health have announced a new partnership to provide biopharmaceutical researchers with access to Guardant's clinicogenomic testing data and Verana's EHR datasets. This collaboration aims to accelerate the development of new therapies and improve patient care by allowing researchers to connect molecular biomarkers with treatment decisions and clinical outcomes. Guardant Health specializes in precision oncology, using data, blood-based tests, and advanced anal", "sentiment_score": 0.405953, "sentiment_label": "Bullish", "relevance_score": 1.0, "sentiment": { "label": "positive", "score": 0.2, "confidence": 0.2 } }, { "source": "alpha_vantage", "title": "Why Is Guardant Health (GH) Stock Soaring Today", "url": "https://www.tradingview.com/news/stockstory:4270c6473094b:0-why-is-guardant-health-gh-stock-soaring-today/", "date": "2026-03-31", "summary": "Guardant Health (GH) stock saw a 5.9% increase after the company announced that its InfinityAI platform's real-world evidence contributed to the approval of the cancer drug ENHERTU® in Japan. This development validates Guardant's AI technology in precision oncology. Despite the recent jump, the stock remains volatile and is down 9.2% year-to-date and 21.2% below its 52-week high.", "sentiment_score": 0.011068, "sentiment_label": "Neutral", "relevance_score": 0.344824, "sentiment": { "label": "neutral", "score": 0.0, "confidence": 0.0 } }, { "source": "alpha_vantage", "title": "Guardant Health real-world data supports Japan approval of ENHERTU for HER2-positive tumors", "url": "https://www.msn.com/en-us/health/other/guardant-health-real-world-data-supports-japan-approval-of-enhertu-for-her2-positive-tumors/ar-AA1ZJdPW?apiversion=v2&domshim=1&noservercache=1&noservertelemetry=1&batchservertelemetry=1&renderwebcomponents=1&wcseo=1", "date": "2026-03-31", "summary": "Guardant Health's real-world data has supported the Japan Pharmaceuticals and Medical Devices Agency's approval of ENHERTU for treating HER2-positive tumors. This approval represents a significant step forward in personalized medicine for these cancer types, leveraging genomic profiling for treatment decisions. The data likely demonstrated the effectiveness or necessity of identifying HER2 status in patients.", "sentiment_score": 0.609125, "sentiment_label": "Bullish", "relevance_score": 1.0, "sentiment": { "label": "positive", "score": 0.681, "confidence": 0.68 } }, { "source": "alpha_vantage", "title": "The Bull Case For Guardant Health (GH) Could Change Following Japan’s ENHERTU Approval Using Its AI Data", "url": "https://simplywall.st/stocks/us/healthcare/nasdaq-gh/guardant-health/news/the-bull-case-for-guardant-health-gh-could-change-following", "date": "2026-03-31", "summary": "Guardant Health's InfinityAI and Guardant360 platforms helped secure regulatory approval for Daiichi Sankyo’s ENHERTU in Japan, demonstrating the growing role of AI-driven real-world data in oncology drug approvals. While this reinforces the value of Guardant's data assets, the company still faces challenges with cash burn and achieving profitability. The approval, alongside partnerships like Verana Health, solidifies Guardant's position in AI-enabled oncology data but raises execution risks in ", "sentiment_score": 0.310222, "sentiment_label": "Somewhat-Bullish", "relevance_score": 1.0, "sentiment": { "label": "positive", "score": 0.477, "confidence": 0.48 } }, { "source": "alpha_vantage", "title": "Guardant Health Inc (GH) Trading Down 3.96% on Mar 30", "url": "https://www.gurufocus.com/news/8756885/guardant-health-inc-gh-trading-down-396-on-mar-30?mobile=true", "date": "2026-03-30", "summary": "Guardant Health Inc (GH) experienced a 3.96% decline in its stock price on March 30, trading down to $84.61. While Wall Street analysts have an average target price of $129.67, suggesting a potential upside, GuruFocus estimates a different fair value of $67.08, implying a downside from the current price. The stock's trading volume was significantly higher than its average daily volume during this period.", "sentiment_score": -0.291249, "sentiment_label": "Somewhat-Bearish", "relevance_score": 1.0, "sentiment": { "label": "neutral", "score": 0.0, "confidence": 0.0 } }, { "source": "alpha_vantage", "title": "Guardant Health’s InfinityAI Real-World Evidence Supports Approval of ENHERTU® for Previously Treated Patients with HER2-Positive Metastatic Solid Tumors in Japan", "url": "https://www.businesswire.com/news/home/20260330846159/en/Guardant-Healths-InfinityAI-Real-World-Evidence-Supports-Approval-of-ENHERTU-for-Previously-Treated-Patients-with-HER2-Positive-Metastatic-Solid-Tumors-in-Japan", "date": "2026-03-30", "summary": "Guardant Health's InfinityAI platform provided crucial real-world evidence, alongside clinical trial data, to support the recent approval of ENHERTU® in Japan. This approval, granted by Japan’s Ministry of Health, Labour and Welfare, is for treating HER2-positive metastatic solid cancers refractory to standard treatments. The collaboration with Daiichi Sankyo highlights the increasing importance of real-world data in expanding access to targeted therapies for rare biomarker-defined patient popul", "sentiment_score": 0.499457, "sentiment_label": "Bullish", "relevance_score": 1.0, "sentiment": { "label": "positive", "score": 0.735, "confidence": 0.74 } }, { "source": "alpha_vantage", "title": "Guardant Health to present new cancer research while stock trades lower amid strong sell signals", "url": "https://tradersunion.com/news/companies/show/1818093-guardant-health-drops-3-96percent-today/", "date": "2026-03-29", "summary": "Guardant Health is set to present 28 abstracts at the AACR26 event, showcasing advancements in cancer diagnostics and research, particularly in methylation-based tumor classification and multiomic testing. Despite this upcoming presentation of new cancer research, the company's stock has experienced a 3.96% intraday drop, trading lower amid strong sell signals and sustained bearish momentum. Technical indicators suggest further downside risk, with the stock positioned below key moving averages a", "sentiment_score": -0.637367, "sentiment_label": "Bearish", "relevance_score": 1.0, "sentiment": { "label": "negative", "score": -0.511, "confidence": 0.51 } }, { "source": "alpha_vantage", "title": "Guardant Health Shares Fall as Market Reacts to Conflict, Policy Deadlines | 2026 - News and Statistics", "url": "https://www.indexbox.io/blog/guardant-health-stock-drops-amid-market-uncertainty-and-low-consumer-confidence/", "date": "2026-03-28", "summary": "Guardant Health's stock declined in afternoon trading, reflecting broader market unease fueled by international conflict and upcoming policy deadlines. This market sentiment also pushed consumer confidence to a three-month low, and the company's shares are now trading below their year-to-date peak and are worth less than their value five years ago. The article also provides details on a report about the composite laboratory reagents industry in the United States, including market analysis, trade", "sentiment_score": -0.621827, "sentiment_label": "Bearish", "relevance_score": 1.0, "sentiment": { "label": "neutral", "score": -0.026, "confidence": 0.03 } }, { "source": "alpha_vantage", "title": "Why Guardant Health (GH) Stock Is Falling Today", "url": "https://www.tradingview.com/news/stockstory:a4995f8d7094b:0-why-guardant-health-gh-stock-is-falling-today/", "date": "2026-03-27", "summary": "Guardant Health (GH) stock fell 3% today due to escalating uncertainty from the U.S.-Iran conflict and Trump administration policy deadlines, which also caused major indices to drop. This follows a 3.4% dip almost a month ago driven by higher-than-expected wholesale inflation data. Guardant Health's shares are highly volatile and have fallen 16.7% year-to-date, trading significantly below its 52-week high.", "sentiment_score": -0.398006, "sentiment_label": "Bearish", "relevance_score": 1.0, "sentiment": { "label": "negative", "score": -0.153, "confidence": 0.15 } }, { "source": "alpha_vantage", "title": "Guardant Health wins at Healthcare Asia Medtech Awards 2026", "url": "https://healthcareasiamagazine.com/co-written-partner/event-news/guardant-health-wins-healthcare-asia-medtech-awards-2026", "date": "2026-03-27", "summary": "Guardant Health Pte Ltd won the Oncology Product Innovation of the Year at the Healthcare Asia Medtech Awards 2026 for its ShieldTM Multi-cancer Detection (MCD) test. This blood test screens for 10 types of cancers, demonstrating 99% overall specificity and 74% sensitivity across six aggressive cancers in recent data. The Shield MCD test has also received Breakthrough Device Designation from the U.S. Food and Drug Administration (FDA).", "sentiment_score": 0.429202, "sentiment_label": "Bullish", "relevance_score": 1.0, "sentiment": { "label": "positive", "score": 0.772, "confidence": 0.77 } }, { "source": "alpha_vantage", "title": "Tempus AI Reinforces Market Position With Collaborations in 2026", "url": "https://www.tradingview.com/news/zacks:5e5cf70e2094b:0-tempus-ai-reinforces-market-position-with-collaborations-in-2026/", "date": "2026-03-26", "summary": "Tempus AI (TEM) is strengthening its market position in 2026 through strategic collaborations with pharmaceutical companies, healthcare institutions, and technology innovators. These partnerships aim to improve clinical outcomes and accelerate drug development by leveraging Tempus's AI expertise and proprietary platforms. Notable collaborations include work with Daiichi Sankyo on an ADC program, Median Technologies for lung nodule characterization, Blood Cancer United for a pediatric AML registr", "sentiment_score": 0.017012, "sentiment_label": "Neutral", "relevance_score": 0.325911, "sentiment": { "label": "neutral", "score": 0.0, "confidence": 0.0 } }, { "source": "pubmed", "pmid": "41991549", "title": "Acute circulating tumor DNA dynamics during and after systemic therapy initiation for advanced triple-negative breast cancer.", "authors": "To B et al.", "journal": "NPJ breast cancer", "date": "2026 Apr 1", "url": "https://pubmed.ncbi.nlm.nih.gov/41991549/", "sentiment": { "label": "negative", "score": -0.599, "confidence": 0.6 } }, { "source": "pubmed", "pmid": "41986681", "title": "How effective is the personalized off-label use of targeted cancer treatment?", "authors": "Meric-Bernstam F", "journal": "Nature", "date": "2026 Apr 1", "url": "https://pubmed.ncbi.nlm.nih.gov/41986681/", "sentiment": { "label": "negative", "score": -0.318, "confidence": 0.32 } }, { "source": "pubmed", "pmid": "41980878", "title": "Clinicopathologic and Molecular Characteristics of Merkel Cell Polyomavirus Positive T-Cell Lymphoproliferative Disorders.", "authors": "Bulterys P et al.", "journal": "The American journal of surgical pathology", "date": "2026 May 1", "url": "https://pubmed.ncbi.nlm.nih.gov/41980878/", "sentiment": { "label": "positive", "score": 0.557, "confidence": 0.56 } }, { "source": "pubmed", "pmid": "41980760", "title": "Stromal biomarker-based framework for identifying pMMR/MSS and dMMR/MSI colorectal cancers with poor outcomes and limited benefit from immunotherapy.", "authors": "Iglesias Coma M et al.", "journal": "Gut", "date": "2026 Apr 1", "url": "https://pubmed.ncbi.nlm.nih.gov/41980760/", "sentiment": { "label": "negative", "score": -0.25, "confidence": 0.25 } }, { "source": "pubmed", "pmid": "41968152", "title": "Branched-chain amino acid catabolism is potentially deficient in pancreatic cancer with high-neural invasion.", "authors": "Michida H et al.", "journal": "Scientific reports", "date": "2026 Apr 1", "url": "https://pubmed.ncbi.nlm.nih.gov/41968152/", "sentiment": { "label": "negative", "score": -0.66, "confidence": 0.66 } }, { "source": "pubmed", "pmid": "41966716", "title": "Is EGFR back? ADCs revive targeted therapy in nasopharyngeal carcinoma.", "authors": "Kanemura H et al.", "journal": "Med (New York, N.Y.)", "date": "2026 Apr 1", "url": "https://pubmed.ncbi.nlm.nih.gov/41966716/", "sentiment": { "label": "positive", "score": 0.34, "confidence": 0.34 } }, { "source": "pubmed", "pmid": "41965791", "title": "PARP inhibition with olaparib and talazoparib for HER2-negative advanced breast cancer-Results from the prospective PRAEGNANT registry.", "authors": "Hörner M et al.", "journal": "NPJ breast cancer", "date": "2026 Apr 1", "url": "https://pubmed.ncbi.nlm.nih.gov/41965791/", "sentiment": { "label": "negative", "score": -0.128, "confidence": 0.13 } }, { "source": "pubmed", "pmid": "41963611", "title": "Outcomes of patients with or without DNA repair pathway alterations: the MD Anderson IMPACT2 study.", "authors": "Venturini J et al.", "journal": "NPJ precision oncology", "date": "2026 Apr 1", "url": "https://pubmed.ncbi.nlm.nih.gov/41963611/", "sentiment": { "label": "neutral", "score": 0.0, "confidence": 0.0 } }, { "source": "pubmed", "pmid": "41962211", "title": "Implementing a molecular prescreening strategy for tumors without public NGS access in a cancer center network: Results from the PREICO project.", "authors": "Sàbat P et al.", "journal": "European journal of cancer (Oxford, England : 1990)", "date": "2026 Apr 4", "url": "https://pubmed.ncbi.nlm.nih.gov/41962211/", "sentiment": { "label": "negative", "score": -0.66, "confidence": 0.66 } }, { "source": "pubmed", "pmid": "41957135", "title": "Impact of tumor location on the efficacy of concurrent chemoradiotherapy for locally advanced non-small cell lung cancer.", "authors": "Ozawa Y et al.", "journal": "British journal of cancer", "date": "2026 Apr 9", "url": "https://pubmed.ncbi.nlm.nih.gov/41957135/", "sentiment": { "label": "negative", "score": -0.718, "confidence": 0.72 } }, { "source": "pubmed", "pmid": "41956545", "title": "Phase 1b study of ABBV-368, tilsotolimod, budigalimab, and nab-paclitaxel in patients with recurrent/metastatic head and neck squamous cell carcinoma.", "authors": "Daste A et al.", "journal": "Journal for immunotherapy of cancer", "date": "2026 Apr 9", "url": "https://pubmed.ncbi.nlm.nih.gov/41956545/", "sentiment": { "label": "neutral", "score": 0.0, "confidence": 0.0 } }, { "source": "pubmed", "pmid": "41956543", "title": "HosTIL territory: mapping the landscape of toxicity in TIL therapy.", "authors": "Woodford R et al.", "journal": "Journal for immunotherapy of cancer", "date": "2026 Apr 9", "url": "https://pubmed.ncbi.nlm.nih.gov/41956543/", "sentiment": { "label": "neutral", "score": 0.0, "confidence": 0.0 } }, { "source": "pubmed", "pmid": "41954928", "title": "Colorectal Cancer and Mortality Risk Among Older Adults With vs Without Adenoma on Prior Colonoscopy.", "authors": "Gupta S et al.", "journal": "JAMA", "date": "2026 Apr 9", "url": "https://pubmed.ncbi.nlm.nih.gov/41954928/", "sentiment": { "label": "negative", "score": -0.758, "confidence": 0.76 } }, { "source": "pubmed", "pmid": "41951768", "title": "High-throughput screening identifies NT-1 that synergizes with MRTX1133 against acquired resistant KRAS(G12D) colorectal cancer.", "authors": "Thielen N et al.", "journal": "NPJ precision oncology", "date": "2026 Apr 8", "url": "https://pubmed.ncbi.nlm.nih.gov/41951768/", "sentiment": { "label": "negative", "score": -0.66, "confidence": 0.66 } }, { "source": "pubmed", "pmid": "41951735", "title": "Multiomics and deep learning dissect regulatory syntax in human development.", "authors": "Liu BB et al.", "journal": "Nature", "date": "2026 Apr 8", "url": "https://pubmed.ncbi.nlm.nih.gov/41951735/", "sentiment": { "label": "neutral", "score": 0.0, "confidence": 0.0 } }, { "source": "pubmed", "pmid": "41950928", "title": "Antibody-drug conjugates in breast cancer: Progress and future directions.", "authors": "Bili Newman A et al.", "journal": "Cell reports. Medicine", "date": "2026 Apr 7", "url": "https://pubmed.ncbi.nlm.nih.gov/41950928/", "sentiment": { "label": "negative", "score": -0.382, "confidence": 0.38 } }, { "source": "pubmed", "pmid": "41945065", "title": "Effectiveness of amivantamab compared with real-world therapies in patients with non-small cell lung cancer with EGFR exon 20 insertion mutations post platinum-based chemotherapy.", "authors": "Wu JY et al.", "journal": "Journal of the Formosan Medical Association = Taiwan yi zhi", "date": "2026 Apr 6", "url": "https://pubmed.ncbi.nlm.nih.gov/41945065/", "sentiment": { "label": "negative", "score": -0.66, "confidence": 0.66 } }, { "source": "pubmed", "pmid": "41938080", "title": "Clinical Concordance of Pan Lung Cancer PCR Panel Covering 167 Actionable Variants Across 11 Genes and Other Validated Assays in the LC-SCRUM-Asia Registry.", "authors": "Matsumoto S et al.", "journal": "JTO clinical and research reports", "date": "2026-04-17", "url": "https://pubmed.ncbi.nlm.nih.gov/41938080/", "sentiment": { "label": "negative", "score": -0.542, "confidence": 0.54 } }, { "source": "pubmed", "pmid": "41935073", "title": "IL1R1 blockade augments CD40 agonist mediated immunity in pancreatic cancer.", "authors": "Boda AR et al.", "journal": "Scientific reports", "date": "2026 Apr 4", "url": "https://pubmed.ncbi.nlm.nih.gov/41935073/", "sentiment": { "label": "negative", "score": -0.66, "confidence": 0.66 } }, { "source": "pubmed", "pmid": "41934464", "title": "Definitive Radiotherapy to the Primary Tumor in Stage IV NSCLC: A Consensus Statement From the International Association for the Study of Lung Cancer Advanced Radiation Technology Subcommittee.", "authors": "McMahon RA et al.", "journal": "Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer", "date": "2026 Apr 3", "url": "https://pubmed.ncbi.nlm.nih.gov/41934464/", "sentiment": { "label": "negative", "score": -0.718, "confidence": 0.72 } }, { "source": "pubmed", "pmid": "41933595", "title": "Safety profile of KRAS G12C inhibitors combined with thoracic radiation therapy.", "authors": "Miller DG et al.", "journal": "Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology", "date": "2026 Mar 3", "url": "https://pubmed.ncbi.nlm.nih.gov/41933595/", "sentiment": { "label": "positive", "score": 0.202, "confidence": 0.2 } }, { "source": "pubmed", "pmid": "41933194", "title": "Treatment monitoring by biomarker analysis in a Phase I dose-expansion study of AZD2811 for relapsed/refractory small-cell lung cancer.", "authors": "Johnson ML et al.", "journal": "British journal of cancer", "date": "2026 Apr 3", "url": "https://pubmed.ncbi.nlm.nih.gov/41933194/", "sentiment": { "label": "negative", "score": -0.66, "confidence": 0.66 } }, { "source": "pubmed", "pmid": "41931739", "title": "Longitudinal, Retrospective Use of a Circulating Tumor DNA Methylation Signature Successfully Captures Small Cell Evolution in a Patient With Metastatic EGFR-Mutant Non-Small Cell Lung Cancer.", "authors": "Patil T et al.", "journal": "JCO precision oncology", "date": "2026-04-17", "url": "https://pubmed.ncbi.nlm.nih.gov/41931739/", "sentiment": { "label": "negative", "score": -0.586, "confidence": 0.59 } }, { "source": "pubmed", "pmid": "41931218", "title": "Sequential Use of Trastuzumab Deruxtecan and Sacituzumab Govitecan in Patients with Breast Cancer: A Pharmacological Approach to Support the Clinical Rationale.", "authors": "Del Re M et al.", "journal": "Drugs", "date": "2026 Apr 3", "url": "https://pubmed.ncbi.nlm.nih.gov/41931218/", "sentiment": { "label": "negative", "score": -0.402, "confidence": 0.4 } }, { "source": "pubmed", "pmid": "41925922", "title": "Alpelisib and Fulvestrant in PIK3CA-mutated hormone receptor-positive HER2-negative advanced breast cancer included in the German PRAEGNANT trial.", "authors": "Hörner M et al.", "journal": "Breast cancer research and treatment", "date": "2026 Apr 2", "url": "https://pubmed.ncbi.nlm.nih.gov/41925922/", "sentiment": { "label": "negative", "score": -0.527, "confidence": 0.53 } }, { "source": "pubmed", "pmid": "41924551", "title": "Key Considerations for Targeting KRAS in Pancreatic Cancer: Potential Impact on the Treatment Paradigm.", "authors": "Eslinger C et al.", "journal": "Drug design, development and therapy", "date": "2026-04-17", "url": "https://pubmed.ncbi.nlm.nih.gov/41924551/", "sentiment": { "label": "negative", "score": -0.66, "confidence": 0.66 } }, { "source": "pubmed", "pmid": "41922144", "title": "Gene testing and prognosis in post-operative recurrent non-small-cell lung cancer: subgroup analyses of WJOG15421L.", "authors": "Matsubara T et al.", "journal": "ESMO open", "date": "2026 Mar 3", "url": "https://pubmed.ncbi.nlm.nih.gov/41922144/", "sentiment": { "label": "negative", "score": -0.66, "confidence": 0.66 } }, { "source": "pubmed", "pmid": "41922143", "title": "Comparative efficacy of zanubrutinib plus obinutuzumab versus last prior treatment in relapsed/refractory follicular lymphoma: growth modulation index analysis from the ROSEWOOD study.", "authors": "Trotman J et al.", "journal": "ESMO open", "date": "2026 Mar 3", "url": "https://pubmed.ncbi.nlm.nih.gov/41922143/", "sentiment": { "label": "positive", "score": 0.382, "confidence": 0.38 } }, { "source": "pubmed", "pmid": "41917211", "title": "Phase 1 study of ceralasertib, an ATR kinase inhibitor, in combination with durvalumab in patients with recurrent or metastatic NSCLC or HNSCC.", "authors": "Lopez JS et al.", "journal": "British journal of cancer", "date": "2026 Mar 3", "url": "https://pubmed.ncbi.nlm.nih.gov/41917211/", "sentiment": { "label": "negative", "score": -0.077, "confidence": 0.08 } }, { "source": "pubmed", "pmid": "41917040", "title": "Loss of luminal lineage drives resistance to next-generation ERα antagonists in pretreated ER(+) HER2(-) locally-advanced or metastatic breast cancer.", "authors": "Liang J et al.", "journal": "Nature communications", "date": "2026 Apr 1", "url": "https://pubmed.ncbi.nlm.nih.gov/41917040/", "sentiment": { "label": "negative", "score": -1.0, "confidence": 1.0 } }, { "source": "pubmed", "pmid": "41910021", "title": "A plain language summary of the updated results from the PHAROS study: the combination of encorafenib plus binimetinib for people with BRAF V600E-mutant metastatic non-small cell lung cancer.", "authors": "Johnson ML et al.", "journal": "Future oncology (London, England)", "date": "2026-04-17", "url": "https://pubmed.ncbi.nlm.nih.gov/41910021/", "sentiment": { "label": "negative", "score": -0.66, "confidence": 0.66 } }, { "source": "pubmed", "pmid": "41903996", "title": "Utility of Circulating Tumor DNA-Based Liquid Biopsies in Patients with Cancer Receiving Immunotherapy.", "authors": "Teixeira MF et al.", "journal": "Surgical oncology clinics of North America", "date": "2026-04-17", "url": "https://pubmed.ncbi.nlm.nih.gov/41903996/", "sentiment": { "label": "negative", "score": -0.791, "confidence": 0.79 } }, { "source": "pubmed", "pmid": "41903301", "title": "Phase Ia/Ib trial of the safety and efficacy of mobocertinib in combination with T-DM1 for patients with HER2-mutant solid tumors (WJOG16022M).", "authors": "Kanemura H et al.", "journal": "European journal of cancer (Oxford, England : 1990)", "date": "2026 May 2", "url": "https://pubmed.ncbi.nlm.nih.gov/41903301/", "sentiment": { "label": "positive", "score": 0.527, "confidence": 0.53 } }, { "source": "pubmed", "pmid": "41896648", "title": "Gotistobart or docetaxel in metastatic squamous non-small cell lung cancer: stage 1 of the randomized phase 3 PRESERVE-003 trial.", "authors": "Cho BC et al.", "journal": "Nature medicine", "date": "2026 Mar 2", "url": "https://pubmed.ncbi.nlm.nih.gov/41896648/", "sentiment": { "label": "negative", "score": -0.66, "confidence": 0.66 } }, { "source": "pubmed", "pmid": "41895789", "title": "Comparison of tissue acquisition techniques for Next-Generation Sequencing of non-small cell lung cancer (NSCLC).", "authors": "Bhamani A et al.", "journal": "BMJ open respiratory research", "date": "2026 Mar 2", "url": "https://pubmed.ncbi.nlm.nih.gov/41895789/", "sentiment": { "label": "negative", "score": -0.46, "confidence": 0.46 } }, { "source": "pubmed", "pmid": "41895314", "title": "Consensus definition of stage III non-small-cell lung cancer technical resectability to standardise inclusion criteria for clinical trials: a multisocietal EORTC-Lung Cancer Group collaboration.", "authors": "Dingemans AC et al.", "journal": "The Lancet. Respiratory medicine", "date": "2026 Mar 2", "url": "https://pubmed.ncbi.nlm.nih.gov/41895314/", "sentiment": { "label": "negative", "score": -0.869, "confidence": 0.87 } }, { "source": "pubmed", "pmid": "41892875", "title": "Baseline tumor burden and outcomes in patients with rare cancers treated with immunotherapy (Southwest Oncology Group trial S1609).", "authors": "Swiecicki PL et al.", "journal": "Cancer", "date": "2026 Apr 1", "url": "https://pubmed.ncbi.nlm.nih.gov/41892875/", "sentiment": { "label": "negative", "score": -0.67, "confidence": 0.67 } }, { "source": "pubmed", "pmid": "41883872", "title": "Molecular complete response to the RIN protocol (regorafenib, ipilimumab, and nivolumab) in a patient with advanced recurrent metastatic mismatch repair proficient/microsatellite stable (pMMR/MSS) rectal cancer.", "authors": "Qadri F et al.", "journal": "Therapeutic advances in medical oncology", "date": "2026-04-17", "url": "https://pubmed.ncbi.nlm.nih.gov/41883872/", "sentiment": { "label": "negative", "score": -0.296, "confidence": 0.3 } }, { "source": "pubmed", "pmid": "41882405", "title": "Pembrolizumab and olaparib in homologous-recombination-deficient metastatic pancreatic cancer: the phase 2 POLAR trial.", "authors": "Park W et al.", "journal": "Nature medicine", "date": "2026 Mar 2", "url": "https://pubmed.ncbi.nlm.nih.gov/41882405/", "sentiment": { "label": "negative", "score": -0.66, "confidence": 0.66 } }, { "source": "pubmed", "pmid": "41880871", "title": "Randomized phase II study of FOLFIRI plus ramucirumab versus FOLFOXIRI plus ramucirumab as first-line treatment for metastatic colorectal cancer: WJOG9216G (RECAST).", "authors": "Kito Y et al.", "journal": "European journal of cancer (Oxford, England : 1990)", "date": "2026 May 2", "url": "https://pubmed.ncbi.nlm.nih.gov/41880871/", "sentiment": { "label": "negative", "score": -0.66, "confidence": 0.66 } }, { "source": "pubmed", "pmid": "41876649", "title": "AI-based chest X-ray prioritization in the lung cancer diagnostic pathway: the LungIMPACT randomized controlled trial.", "authors": "Woznitza N et al.", "journal": "Nature medicine", "date": "2026 Mar 2", "url": "https://pubmed.ncbi.nlm.nih.gov/41876649/", "sentiment": { "label": "negative", "score": -0.66, "confidence": 0.66 } }, { "source": "pubmed", "pmid": "41874648", "title": "Real-world effectiveness of avelumab, pembrolizumab, and enfortumab vedotin in patients with advanced urothelial carcinoma with squamous differentiation (ARON-2EV).", "authors": "Mollica V et al.", "journal": "Cancer immunology, immunotherapy : CII", "date": "2026 Mar 2", "url": "https://pubmed.ncbi.nlm.nih.gov/41874648/", "sentiment": { "label": "positive", "score": 0.25, "confidence": 0.25 } }, { "source": "pubmed", "pmid": "41872602", "title": "Implementation of the NHS England Lung Cancer Screening Programme over 5 years.", "authors": "Lee RW et al.", "journal": "Nature medicine", "date": "2026 Mar 2", "url": "https://pubmed.ncbi.nlm.nih.gov/41872602/", "sentiment": { "label": "negative", "score": -0.66, "confidence": 0.66 } }, { "source": "pubmed", "pmid": "41871874", "title": "Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of renal cell carcinoma, version 3.0.", "authors": "McKay RR et al.", "journal": "Journal for immunotherapy of cancer", "date": "2026 Mar 2", "url": "https://pubmed.ncbi.nlm.nih.gov/41871874/", "sentiment": { "label": "negative", "score": -0.66, "confidence": 0.66 } }, { "source": "pubmed", "pmid": "41870735", "title": "Efficacy and safety of trastuzumab biosimilar CT-P6 plus SOX or CapeOX in HER2-positive advanced gastric cancer: a multicenter phase II KSCC-TROX study.", "authors": "Oki E et al.", "journal": "Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association", "date": "2026 Mar 2", "url": "https://pubmed.ncbi.nlm.nih.gov/41870735/", "sentiment": { "label": "negative", "score": -0.153, "confidence": 0.15 } }, { "source": "pubmed", "pmid": "41866411", "title": "Efficacy and safety of peptide radionuclide therapy with (177)Lu-DOTATATE in Japanese patients with advanced neuroendocrine neoplasm: a multicenter retrospective study (JON2203-N).", "authors": "Okamoto K et al.", "journal": "Journal of gastroenterology", "date": "2026 Mar 2", "url": "https://pubmed.ncbi.nlm.nih.gov/41866411/", "sentiment": { "label": "positive", "score": 0.586, "confidence": 0.59 } }, { "source": "pubmed", "pmid": "41864749", "title": "Survival outcome of VATS compared with open lobectomy for lung cancer: an individual patient data meta-analysis of randomised trials.", "authors": "Harris RA et al.", "journal": "Lancet (London, England)", "date": "2026 Mar 2", "url": "https://pubmed.ncbi.nlm.nih.gov/41864749/", "sentiment": { "label": "negative", "score": -0.66, "confidence": 0.66 } }, { "source": "pubmed", "pmid": "41861751", "title": "Sacituzumab govitecan in patients with metastatic breast cancer: pooled safety analysis of data from patients in North America, Europe, and Asia.", "authors": "Rugo HS et al.", "journal": "ESMO open", "date": "2026 Mar 1", "url": "https://pubmed.ncbi.nlm.nih.gov/41861751/", "sentiment": { "label": "negative", "score": -0.382, "confidence": 0.38 } }, { "source": "pubmed", "pmid": "41861516", "title": "Multidisciplinary international expert consensus recommendations on tissue acquisition in non-small cell lung cancer.", "authors": "Lee P et al.", "journal": "EBioMedicine", "date": "2026-04-17", "url": "https://pubmed.ncbi.nlm.nih.gov/41861516/", "sentiment": { "label": "negative", "score": -0.46, "confidence": 0.46 } }, { "source": "pubmed", "pmid": "41860053", "title": "AGMT mCRC Registry Third-Line and Beyond: a multicentric real-world platform with integrated imaging and biosample database for later-line metastatic colorectal cancer.", "authors": "Huemer F et al.", "journal": "Future oncology (London, England)", "date": "2026-04-17", "url": "https://pubmed.ncbi.nlm.nih.gov/41860053/", "sentiment": { "label": "negative", "score": -0.66, "confidence": 0.66 } }, { "source": "news", "source_name": "Ipspace.net", "title": "Testing FRRouting Pull Requests with netlab", "description": "Every other blue moon, I discover a bug in FRRouting (example). Because the FRRouting developers care about their work, it usually gets fixed within a few days, often resulting in a “can you test this PR?” question.\nIt turns out that’s surprisingly easy to do…", "url": "https://blog.ipspace.net/2026/04/frr-pr-testing/", "date": "2026-04-16", "published_at": "2026-04-16T05:50:00Z", "sentiment": { "label": "positive", "score": 0.807, "confidence": 0.81 } }, { "source": "news", "source_name": "Thechronicle.com.gh", "title": "Eduwatch exposes inequality in Ghana’s education system", "description": "A nationwide monitoring report by  Africa Education Watch (Africa Eduwatch), has exposed deepening inequalities in Ghana’s education system and a growing culture of impunity over examination malpractice, warning that both trends threaten access and learning i…", "url": "https://thechronicle.com.gh/eduwatch-exposes-inequality-in-ghanas-education-system/", "date": "2026-04-16", "published_at": "2026-04-16T05:10:20Z", "sentiment": { "label": "negative", "score": -0.625, "confidence": 0.62 } }, { "source": "news", "source_name": "Thechronicle.com.gh", "title": "Tema Region ECG spends GH¢13 Million on transformers", "description": "The Tema Region of the Electricity Company of Ghana (ECG) spent a total of GH¢13,079,669 on transformer replacements for the last quarter of 2025 and the first quarter of 2026. This information was disclosed to a section of the media by Ing Emmanuel Ankomah, …", "url": "https://thechronicle.com.gh/tema-region-ecg-spends-gh¢13-million-on-transformers/", "date": "2026-04-16", "published_at": "2026-04-16T05:02:57Z", "sentiment": { "label": "neutral", "score": 0.0, "confidence": 0.0 } }, { "source": "news", "source_name": "Pypi.org", "title": "expaloma added to PyPI", "description": "JAX/Equinox port of espaloma-charge partial charge inference (bundled v0.0.8 weights)", "url": "https://pypi.org/project/expaloma/", "date": "2026-04-16", "published_at": "2026-04-16T03:28:11Z", "sentiment": { "label": "neutral", "score": 0.0, "confidence": 0.0 } }, { "source": "news", "source_name": "Github.com", "title": "Does Gas Town 'steal' usage from users' LLM credits to improve itself?", "description": "gastown-release.formula.toml and beads-release.formula.toml causes local Gas Town installation to review open Issues on github.com/steveyegge/gastown/actions, burning through usage on subscribed LL...", "url": "https://github.com/gastownhall/gastown/issues/3649", "date": "2026-04-15", "published_at": "2026-04-15T20:49:48Z", "sentiment": { "label": "positive", "score": 0.296, "confidence": 0.3 } }, { "source": "news", "source_name": "Pypi.org", "title": "amerta added to PyPI", "description": "1D Saint-Venant (shallow water) equations solver: MUSCL-HLLC + SSP-RK2", "url": "https://pypi.org/project/amerta/", "date": "2026-04-15", "published_at": "2026-04-15T17:38:41Z", "sentiment": { "label": "neutral", "score": 0.0, "confidence": 0.0 } }, { "source": "news", "source_name": "Plos.org", "title": "Disorientation patterns of loggerhead sea turtle (Caretta caretta) hatchlings in Pinellas County, Florida, USA", "description": "The disorientation of loggerhead sea turtle (Caretta caretta) hatchlings, primarily caused by artificial lighting, poses a significant threat to their survival, as they rely on environmental cues to reach the ocean. In this study, we analyzed data from nestin…", "url": "https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0347104", "date": "2026-04-15", "published_at": "2026-04-15T14:00:00Z", "sentiment": { "label": "negative", "score": -0.361, "confidence": 0.36 } }, { "source": "news", "source_name": "Thechronicle.com.gh", "title": "POLICE ARREST THREE IN ACCRA DRUG OPERATION", "description": "The Ghana Police Service has arrested three suspects in connection with possession of narcotic drugs and prohibited drug-related activities in the Accra metropolis. Acting on intelligence received on April 10, 2026, the Special Operations Assistant to the Ins…", "url": "https://thechronicle.com.gh/police-arrest-three-in-accra-drug-operation/", "date": "2026-04-15", "published_at": "2026-04-15T13:37:20Z", "sentiment": { "label": "negative", "score": -0.428, "confidence": 0.43 } }, { "source": "news", "source_name": "ZyCrypto", "title": "Beyond Bitcoin: Top 5 Multi-Crypto Mining Titans", "description": "A Comparative Analysis of Algorithm-Agile Mining Operations March 2026 Executive Summary The global cryptocurrency mining industry is undergoing a structural bifurcation. A first tier of operators — those locked into single-algorithm Bitcoin infrastructure — …", "url": "https://zycrypto.com/beyond-bitcoin-top-5-multi-crypto-mining-titans/", "date": "2026-04-15", "published_at": "2026-04-15T12:00:24Z", "sentiment": { "label": "positive", "score": 0.202, "confidence": 0.2 } }, { "source": "news", "source_name": "Super-memory.com", "title": "Good Sleep, Good Learning (2012)", "description": "Article URL: https://super-memory.com/articles/sleep.htm\nComments URL: https://news.ycombinator.com/item?id=47776557\nPoints: 4\n# Comments: 1", "url": "https://super-memory.com/articles/sleep.htm", "date": "2026-04-15", "published_at": "2026-04-15T09:11:18Z", "sentiment": { "label": "positive", "score": 0.7, "confidence": 0.7 } }, { "source": "news", "source_name": "Thechronicle.com.gh", "title": "Six Remanded Over GH¢14.3m Gold Robbery at Adabraka", "description": "An Accra Circuit Court presided over by His Honour Dennis Eyram Benson has remanded six men into police custody for their alleged involvement in a high-value robbery at Adabraka in Accra. The accused persons — Saum Mohammed alias Fariwata (A1), Alhassan Iliya…", "url": "https://thechronicle.com.gh/six-remanded-over-gh¢14-3m-gold-robbery-at-adabraka-2/", "date": "2026-04-15", "published_at": "2026-04-15T05:16:31Z", "sentiment": { "label": "positive", "score": 0.361, "confidence": 0.36 } }, { "source": "news", "source_name": "Thechronicle.com.gh", "title": "Nana Serwaa Bruwaa II: A beacon of holistic and sustainable development at Akrokerri", "description": "In the heart of the Adansi North District of the Ashanti Region, a transformative leader is redefining the traditional role of a Queenmother. Nana Serwaa Bruwaa II, the Queenmother of the Akrokerri Sub-Divisional Council Area has emerged as a rare and multifa…", "url": "https://thechronicle.com.gh/nana-serwaa-bruwaa-ii-a-beacon-of-holistic-and-sustainable-development-at-akrokerri/", "date": "2026-04-15", "published_at": "2026-04-15T05:14:18Z", "sentiment": { "label": "positive", "score": 0.637, "confidence": 0.64 } }, { "source": "news", "source_name": "Thechronicle.com.gh", "title": "Sachet water prices rise in Tema, despite calls to suspend increases", "description": "Some sachet water retailers in Tema have increased the price of a single sachet from GH¢0.50 to GH¢0.70 despite recent calls by authorities to suspend price hikes. The increment follows a pricing recommendation by the National Association of Sachet and Packag…", "url": "https://thechronicle.com.gh/sachet-water-prices-rise-in-tema-despite-calls-to-suspend-increases/", "date": "2026-04-15", "published_at": "2026-04-15T05:12:49Z", "sentiment": { "label": "positive", "score": 0.193, "confidence": 0.19 } }, { "source": "news", "source_name": "Github.com", "title": "Show HN: OpenRig – agent harness that runs Claude Code and Codex as one system", "description": "I've been running Claude Code and Codex together every day. At some point I figured out you can use tmux to let them talk to each other, so I started doing that. Once they could coordinate, I kept adding more agents. Before long I had a whole team working tog…", "url": "https://github.com/mvschwarz/openrig", "date": "2026-04-14", "published_at": "2026-04-14T23:46:40Z", "sentiment": { "label": "neutral", "score": 0.0, "confidence": 0.0 } }, { "source": "news", "source_name": "Thechronicle.com.gh", "title": "Six Remanded Over GH¢14.3m Gold Robbery at Adabraka", "description": "An Accra Circuit Court presided over by His Honour Dennis Eyram Benson has remanded six men into police custody for their alleged involvement in a high-value robbery at Adabraka in Accra. The accused persons — Saum Mohammed alias Fariwata (A1), Alhassan Iliya…", "url": "https://thechronicle.com.gh/six-remanded-over-gh¢14-3m-gold-robbery-at-adabraka/", "date": "2026-04-14", "published_at": "2026-04-14T19:11:45Z", "sentiment": { "label": "positive", "score": 0.361, "confidence": 0.36 } }, { "source": "news", "source_name": "Github.com", "title": "Show HN: Ballast – a free, local-first fitness tracker (no cloud, no account)", "description": "Article URL: https://github.com/N-O-P-E/Ballast\nComments URL: https://news.ycombinator.com/item?id=47769073\nPoints: 1\n# Comments: 0", "url": "https://github.com/N-O-P-E/Ballast", "date": "2026-04-14", "published_at": "2026-04-14T18:06:36Z", "sentiment": { "label": "positive", "score": 0.494, "confidence": 0.49 } }, { "source": "news", "source_name": "Github.com", "title": "Show HN: MCP server for persistent context and safety in Claude Code", "description": "Article URL: https://github.com/AxmeAI/axme-code/\nComments URL: https://news.ycombinator.com/item?id=47768862\nPoints: 2\n# Comments: 1", "url": "https://github.com/AxmeAI/axme-code/", "date": "2026-04-14", "published_at": "2026-04-14T17:51:38Z", "sentiment": { "label": "positive", "score": 0.421, "confidence": 0.42 } }, { "source": "news", "source_name": "Theregister.com", "title": "GitHub invokes spirit of Phabricator with preview of Stacked PRs", "description": "Long-familiar workflow lets developers split big code changes into smaller, easier-to-review chunks\nGitHub has unveiled Stacked PRs, a new feature aimed at making large pull requests easier to review, manage, and move through the pipeline faster.…", "url": "https://www.theregister.com/2026/04/14/github_stacked_prs/", "date": "2026-04-14", "published_at": "2026-04-14T17:03:19Z", "sentiment": { "label": "positive", "score": 0.542, "confidence": 0.54 } }, { "source": "news", "source_name": "Github.com", "title": "Show HN: Claude Control – macOS dashboard for managing Claude Code sessions", "description": "Article URL: https://github.com/sverrirsig/claude-control\nComments URL: https://news.ycombinator.com/item?id=47765520\nPoints: 1\n# Comments: 0", "url": "https://github.com/sverrirsig/claude-control", "date": "2026-04-14", "published_at": "2026-04-14T13:39:44Z", "sentiment": { "label": "neutral", "score": 0.0, "confidence": 0.0 } }, { "source": "news", "source_name": "Github.com", "title": "Show HN: Kontext CLI – Credential broker for AI coding agents in Go", "description": "Open-source CLI for AI coding agents. Give your coding agents access to services without exposing keys. - kontext-security/kontext-cli", "url": "https://github.com/kontext-security/kontext-cli", "date": "2026-04-14", "published_at": "2026-04-14T13:26:53Z", "sentiment": { "label": "positive", "score": 0.206, "confidence": 0.21 } }, { "source": "news", "source_name": "43rumors.com", "title": "Panasonic 25th anniversary: Chinese socials bet on the lunch of many new MFT cameras!", "description": "This is going to be a very important year for Panasonic. While I am confident we will get at least one new MFT model for Panasonic’s 25th anniversary, Chinese bloggers are even more excited than I am. This is what they expect: GX Series (Retro Rangefinder …", "url": "https://www.43rumors.com/panasonic-25th-anniversary-chinese-socials-bet-on-the-lunch-of-many-new-mft-cameras/", "date": "2026-04-14", "published_at": "2026-04-14T12:51:57Z", "sentiment": { "label": "positive", "score": 0.806, "confidence": 0.81 } }, { "source": "news", "source_name": "Thechronicle.com.gh", "title": "Gov’t misses target in latest Treasury Bill auction", "description": "The Government has missed its borrowing target in the latest Treasury Bill auction, recording a shortfall in the total amount accepted from the market. ​The auction results published by the Bank of Ghana for the tender held on April 10, 2026, said the Governm…", "url": "https://thechronicle.com.gh/govt-misses-target-in-latest-treasury-bill-auction/", "date": "2026-04-14", "published_at": "2026-04-14T08:05:52Z", "sentiment": { "label": "positive", "score": 0.221, "confidence": 0.22 } }, { "source": "news", "source_name": "Lawyersgunsmoneyblog.com", "title": "Into the Wood Chipper", "description": "Marisa Kabas has an excerpt from looks like a fascinating new book by a former top USAID official: Without introductions, Joel, who was eating a frozen Indian dinner, jumped right in. “In full transparency, we’re drawing down USAID,” he said. “We’d like you t…", "url": "https://www.lawyersgunsmoneyblog.com/2026/04/into-the-wood-chipper", "date": "2026-04-14", "published_at": "2026-04-14T00:46:49Z", "sentiment": { "label": "positive", "score": 0.852, "confidence": 0.85 } }, { "source": "news", "source_name": "Github.com", "title": "GitHub Stacked PRs", "description": "Break large changes into small, reviewable, stacked pull requests with first-class GitHub support.", "url": "https://github.github.com/gh-stack/", "date": "2026-04-13", "published_at": "2026-04-13T20:36:49Z", "sentiment": { "label": "positive", "score": 0.402, "confidence": 0.4 } }, { "source": "news", "source_name": "The Sun Chronicle", "title": "Central Mass college may not have enough resources to stay open, state warns", "description": "A small Massachusetts private Catholic college may not have “sufficient resources” to keep operating and continue educating students this year and next, according to a warning from state officials on April 10.", "url": "https://www.thesunchronicle.com/news/local_news/central-mass-college-may-not-have-enough-resources-to-stay-open-state-warns/article_f0caf3f5-c2d0-4e79-95ea-e52bc98ea722.html", "date": "2026-04-13", "published_at": "2026-04-13T18:01:00Z", "sentiment": { "label": "negative", "score": -0.421, "confidence": 0.42 } }, { "source": "news", "source_name": "GlobeNewswire", "title": "Companion Diagnostics Market Size is Projected to Hit USD 26.38 Billion by 2035 – SNS Insider", "description": "Precision Medicine Revolution and Rising Cancer Prevalence Drive 11.9% CAGR as Healthcare Shifts Toward Targeted Therapies. Precision Medicine Revolution and Rising Cancer Prevalence Drive 11.9% CAGR as Healthcare Shifts Toward Targeted Therapies.", "url": "https://www.globenewswire.com/news-release/2026/04/13/3272705/0/en/Companion-Diagnostics-Market-Size-is-Projected-to-Hit-USD-26-38-Billion-by-2035-SNS-Insider.html", "date": "2026-04-13", "published_at": "2026-04-13T15:30:00Z", "sentiment": { "label": "negative", "score": -0.869, "confidence": 0.87 } }, { "source": "news", "source_name": "Thechronicle.com.gh", "title": "Pay Cocoa Farmers, Not Party Execs –Minority", "description": "The Minority in Parliament has criticised the governing National Democratic Congress (NDC), accusing it of placing political interests ahead of the welfare of cocoa farmers at a time when the sector is facing significant challenges. The criticism was led by t…", "url": "https://thechronicle.com.gh/pay-cocoa-farmers-not-party-execs-minority/", "date": "2026-04-13", "published_at": "2026-04-13T12:37:54Z", "sentiment": { "label": "negative", "score": -0.715, "confidence": 0.71 } }, { "source": "news", "source_name": "Pypi.org", "title": "band-sdk 0.2.7", "description": "A Python SDK for Thenvoi API", "url": "https://pypi.org/project/band-sdk/", "date": "2026-04-13", "published_at": "2026-04-13T02:23:49Z", "sentiment": { "label": "neutral", "score": 0.0, "confidence": 0.0 } }, { "source": "news", "source_name": "Pypi.org", "title": "ticker-classifier added to PyPI", "description": "A robust stock, crypto, and forex classifier with async support.", "url": "https://pypi.org/project/ticker-classifier/", "date": "2026-04-12", "published_at": "2026-04-12T10:03:15Z", "sentiment": { "label": "positive", "score": 0.625, "confidence": 0.62 } }, { "source": "news", "source_name": "Idratherbewriting.com", "title": "Podcast: How valuable are agent skills? Conversation with Larah Vasquez and Fabrizio Ferri-Benedetti", "description": "In this podcast, I chat with Larah Vasquez and Fabrizio Ferri-Benedetti about using skills to extend AI capabilities, the future of agentic engineering, local models like Qwen and Gemma, and whether the tech writer role is shifting into automation architectur…", "url": "https://idratherbewriting.com/blog/ai-skills-agentic-workflows-larah-fabrizio", "date": "2026-04-12", "published_at": "2026-04-12T07:00:00Z", "sentiment": { "label": "positive", "score": 0.743, "confidence": 0.74 } }, { "source": "news", "source_name": "Brennan.day", "title": "The End of Eleventy", "description": "Build Awesome is a rebrand of 11ty/Eleventy, backed by a successful $40k Kickstarter. But this attempt to monetize static site generators repeats the same mistakes that killed Gatsby and Stackbit—and misunderstands who actually builds static sites.", "url": "https://brennan.day/the-end-of-eleventy/", "date": "2026-04-12", "published_at": "2026-04-12T01:55:48Z", "sentiment": { "label": "negative", "score": -0.857, "confidence": 0.86 } }, { "source": "news", "source_name": "Activistpost.com", "title": "The Lost Art of Medicine: What Maimonides Knew That We Forgot", "description": "Contemporary medicine is not failing for lack of knowledge. It is failing under the weight of its own complexity. The present era is defined by unprecedented access to data, advanced technologies, an ever-expanding network of subspecialties, and a dense archi…", "url": "https://www.activistpost.com/the-lost-art-of-medicine-what-maimonides-knew-that-we-forgot/", "date": "2026-04-11", "published_at": "2026-04-11T16:02:48Z", "sentiment": { "label": "negative", "score": -0.183, "confidence": 0.18 } }, { "source": "news", "source_name": "Sachachua.com", "title": "Org Mode: Tangle Emacs config snippets to different files and add boilerplate", "description": "I want to organize the functions in my Emacs configuration so that they are easier for me to test and so that other people can load them from my repository. Instead of copying multiple code blogs from my blog posts or my exported Emacs configuration, it would…", "url": "https://sachachua.com/blog/2026/04/org-mode-tangle-emacs-config-snippets-to-different-files-and-add-boilerplate/", "date": "2026-04-11", "published_at": "2026-04-11T14:13:19Z", "sentiment": { "label": "positive", "score": 0.477, "confidence": 0.48 } }, { "source": "news", "source_name": "Pypi.org", "title": "afteragent 0.2.0", "description": "Capture agent runs, diagnose failure patterns, and generate workflow interventions.", "url": "https://pypi.org/project/afteragent/", "date": "2026-04-11", "published_at": "2026-04-11T13:44:28Z", "sentiment": { "label": "negative", "score": -0.511, "confidence": 0.51 } }, { "source": "news", "source_name": "Tom's Hardware UK", "title": "Tests show $30,000 AI GPUs are terrible password crackers — RTX 5090 gaming GPU outperforms Nvidia H200 and AMD MI300X", "description": "A research team at Specops benchmarked an RTX 5090, against two AI datacenter GPUs with Hashcat to see which GPU is the better password cracker. Spoiler alert, the RTX 5090 was the winner.", "url": "https://www.tomshardware.com/pc-components/gpus/tests-show-usd30-000-ai-gpus-are-terrible-password-crackers-h200-and-mi300x-outperformed-by-rtx-5090", "date": "2026-04-11", "published_at": "2026-04-11T10:20:00Z", "sentiment": { "label": "positive", "score": 0.9, "confidence": 0.9 } }, { "source": "news", "source_name": "GoodHousekeeping.com", "title": "Gabby Logan’s complete weekly fitness regime at 52", "description": "Gabby Logan’s complete weekly fitness regime at 52goodhousekeeping.com", "url": "https://www.goodhousekeeping.com/uk/health/a70986049/gabby-logan-weekly-fitness-rerime/", "date": "2026-04-11", "published_at": "2026-04-11T07:03:53Z", "sentiment": { "label": "positive", "score": 0.494, "confidence": 0.49 } }, { "source": "news", "source_name": "Github.com", "title": "Show HN: Dux, a TUI Agent Multiplexer", "description": "Hey HN!I built this over the past couple of weeks out of frustration of not having something like Claude Code Desktop, Conductor, Emdash and a few others in a Linux Environment (and a Windows/WSL environment).Dux takes some of the good learnings from most of …", "url": "https://github.com/patrickdappollonio/dux", "date": "2026-04-11", "published_at": "2026-04-11T06:05:03Z", "sentiment": { "label": "negative", "score": -0.382, "confidence": 0.38 } }, { "source": "news", "source_name": "Github.com", "title": "Show HN: Collabmem – a memory system for long-term collaboration with AI", "description": "Hello HN! I built collabmem, a simple memory system for long-term collaboration between humans and AI assistants. And it's easy to install, just ask Claude Code: Install the long-term collaboration memory system by cloning https://github.com/visionscaper/coll…", "url": "https://github.com/visionscaper/collabmem", "date": "2026-04-11", "published_at": "2026-04-11T01:02:17Z", "sentiment": { "label": "positive", "score": 0.493, "confidence": 0.49 } }, { "source": "news", "source_name": "Pypi.org", "title": "wageslave 0.2.1", "description": "Run git/gh with personal GitHub credentials inside Docker containers", "url": "https://pypi.org/project/wageslave/0.2.1/", "date": "2026-04-10", "published_at": "2026-04-10T18:09:51Z", "sentiment": { "label": "neutral", "score": 0.0, "confidence": 0.0 } }, { "source": "news", "source_name": "Pypi.org", "title": "wageslave 0.2.0", "description": "Run git/gh with personal GitHub credentials inside Docker containers", "url": "https://pypi.org/project/wageslave/0.2.0/", "date": "2026-04-10", "published_at": "2026-04-10T18:02:42Z", "sentiment": { "label": "neutral", "score": 0.0, "confidence": 0.0 } }, { "source": "news", "source_name": "Pypi.org", "title": "wageslave 0.1.0", "description": "Run git/gh with personal GitHub credentials inside Docker containers", "url": "https://pypi.org/project/wageslave/0.1.0/", "date": "2026-04-10", "published_at": "2026-04-10T17:43:09Z", "sentiment": { "label": "neutral", "score": 0.0, "confidence": 0.0 } }, { "source": "news", "source_name": "Pypi.org", "title": "wageslave added to PyPI", "description": "Run git/gh with personal GitHub credentials inside Docker containers", "url": "https://pypi.org/project/wageslave/", "date": "2026-04-10", "published_at": "2026-04-10T17:43:04Z", "sentiment": { "label": "neutral", "score": 0.0, "confidence": 0.0 } }, { "source": "news", "source_name": "Thechronicle.com.gh", "title": "Teacher, two farmers arraigned over alleged criminal activities in Nkwanta", "description": "Three persons, a teacher and two farmers, have been arrested at Nkwanta in the Oti Region and arraigned before a Circuit Court in Accra over their alleged involvement in a series of criminal activities. The accused persons are Cosmos Yentumi (A1), 22 and Atta…", "url": "https://thechronicle.com.gh/teacher-two-farmers-arraigned-over-alleged-criminal-activities-in-nkwanta/", "date": "2026-04-10", "published_at": "2026-04-10T11:06:53Z", "sentiment": { "label": "negative", "score": -0.902, "confidence": 0.9 } }, { "source": "news", "source_name": "YouTube", "title": "ENTERTAINMENT GH with OLA MICHAEL on NEAT 100.9 FM 9/04/2026", "description": "ENTERTAINMENT GH with OLA MICHAEL on NEAT 100.9 FM 9/04/2026youtube.com", "url": "https://www.youtube.com/supported_browsers?next_url=https%3A%2F%2Fwww.youtube.com%2Fwatch%3Fv%3DV7rvtrU1iDw", "date": "2026-04-10", "published_at": "2026-04-10T10:41:02Z", "sentiment": { "label": "positive", "score": 0.939, "confidence": 0.94 } }, { "source": "news", "source_name": "Pypi.org", "title": "release-status added to PyPI", "description": "CLI tool to show release/deployment status across multiple projects", "url": "https://pypi.org/project/release-status/", "date": "2026-04-10", "published_at": "2026-04-10T10:12:44Z", "sentiment": { "label": "neutral", "score": 0.0, "confidence": 0.0 } }, { "source": "news", "source_name": "Luxurydaily.com", "title": "Singer Renée Rapp carries Stella McCartney’s Falabella bag forward", "description": "Seventeen years on, the British fashion house’s most beloved accessory finds a new spokesperson.", "url": "https://www.luxurydaily.com/singer-renee-rapp-carries-stella-mccartneys-falabella-bag-forward/", "date": "2026-04-10", "published_at": "2026-04-10T08:45:10Z", "sentiment": { "label": "positive", "score": 0.556, "confidence": 0.56 } }, { "source": "news", "source_name": "C-sharpcorner.com", "title": "Superpowers by obra: What It Is and How to Use It to Improve AI Coding", "description": "Superpowers by obra: A workflow-first approach to AI coding. Standardize skills for Claude, Cursor, Codex, and more. Improve AI coding habits with TDD and code review.", "url": "https://www.c-sharpcorner.com/article/superpowers-by-obra-what-it-is-and-how-to-use-it-to-improve-ai-coding/", "date": "2026-04-10", "published_at": "2026-04-10T04:32:14Z", "sentiment": { "label": "positive", "score": 0.726, "confidence": 0.73 } }, { "source": "news", "source_name": "ComingSoon.net", "title": "General Hospital’s Carly Actor Confirms Appearance in a New Movie", "description": "Laura Wright, who plays Carly Spencer in General Hospital, took to social media to confirm her role in an upcoming satire comedy movie. Introduced in 2005, Wright’s character is the daughter of John Durant and the late Nurse Bobbie Spencer in GH. The upcoming…", "url": "https://www.comingsoon.net/tv/news/2118455-general-hospital-carly-laura-wright-new-movie", "date": "2026-04-10", "published_at": "2026-04-10T04:16:38Z", "sentiment": { "label": "positive", "score": 0.542, "confidence": 0.54 } }, { "source": "news", "source_name": "David.coffee", "title": "I Still Prefer MCP over Skills", "description": "Why I believe the Model Context Protocol (MCP) is a better architectural pattern than the emerging “Skills” trend for LLM tool integration.", "url": "https://david.coffee/i-still-prefer-mcp-over-skills/", "date": "2026-04-10", "published_at": "2026-04-10T02:01:48Z", "sentiment": { "label": "positive", "score": 0.44, "confidence": 0.44 } }, { "source": "news", "source_name": "Pypi.org", "title": "gh-clean added to PyPI", "description": "Remote GitHub branch cleanup reporting tool", "url": "https://pypi.org/project/gh-clean/", "date": "2026-04-10", "published_at": "2026-04-10T00:56:17Z", "sentiment": { "label": "neutral", "score": 0.0, "confidence": 0.0 } }, { "source": "news", "source_name": "Timharford.com", "title": "The usefulness of useless knowledge", "description": "Of honey bees, long shots, and the usefulness of useless knowledge...", "url": "https://timharford.com/2026/04/the-usefulness-of-useless-knowledge/", "date": "2026-04-09", "published_at": "2026-04-09T16:59:00Z", "sentiment": { "label": "negative", "score": -0.296, "confidence": 0.3 } }, { "source": "news", "source_name": "GlobeNewswire", "title": "Global Noninvasive Cancer Diagnostics Market to Reach $165.2 Billion by 2030 as Liquid Biopsy, AI-Enabled Screening and Multi-Cancer Detection Tests Transform Oncology", "description": "Market growth is driven by rising cancer prevalence, demand for minimally invasive procedures, and advances in precision diagnostics....", "url": "https://www.globenewswire.com/news-release/2026/04/09/3271135/0/en/Global-Noninvasive-Cancer-Diagnostics-Market-to-Reach-165-2-Billion-by-2030-as-Liquid-Biopsy-AI-Enabled-Screening-and-Multi-Cancer-Detection-Tests-Transform-Oncology.html", "date": "2026-04-09", "published_at": "2026-04-09T14:12:00Z", "sentiment": { "label": "negative", "score": -0.823, "confidence": 0.82 } }, { "source": "news", "source_name": "Streetartutopia.com", "title": "Made You Dream (12 Photos)", "description": "Some street art changes a wall. These pieces change the whole feeling of a place. From a rainbow staircase in Sardinia to a glowing betta fish in Portugal, a giant box opening across a real building, and a shark scene hiding under concrete, every work here tu…", "url": "https://streetartutopia.com/2026/04/09/street-art-that-change-the-feeling-of-a-place/", "date": "2026-04-09", "published_at": "2026-04-09T14:01:00Z", "sentiment": { "label": "positive", "score": 0.077, "confidence": 0.08 } }, { "source": "news", "source_name": "Plos.org", "title": "Cell-free RNA reveals host and microbial correlates of broadly neutralizing antibody development against HIV", "description": "Author summary A subset of people living with HIV develop broadly neutralizing antibodies (bNAbs), a phenomenon that remains poorly understood but relevant to vaccine development. We applied combined cell-free RNA and DNA sequencing to 42 longitudinal plasma …", "url": "https://journals.plos.org/plospathogens/article?id=10.1371/journal.ppat.1014066", "date": "2026-04-09", "published_at": "2026-04-09T14:00:00Z", "sentiment": { "label": "neutral", "score": 0.0, "confidence": 0.0 } }, { "source": "news", "source_name": "Thechronicle.com.gh", "title": "Citi FM/Channel One TV Extend Easter Orphan Project to Prisons", "description": "Management and staff of Citi FM and Channel One TV, through the Citi FM Foundation, have expanded their annual Easter Orphan Project to include prisons, orphanages and rehabilitation centres across the country, reaching a broader segment of vulnerable populat…", "url": "https://thechronicle.com.gh/citi-fm-channel-one-tv-extend-easter-orphan-project-to-prisons/", "date": "2026-04-09", "published_at": "2026-04-09T11:31:11Z", "sentiment": { "label": "positive", "score": 0.153, "confidence": 0.15 } }, { "source": "news", "source_name": "Pypi.org", "title": "product-dl added to PyPI", "description": "Youtube-DL but for product pages.", "url": "https://pypi.org/project/product-dl/", "date": "2026-04-09", "published_at": "2026-04-09T04:10:38Z", "sentiment": { "label": "neutral", "score": 0.0, "confidence": 0.0 } }, { "source": "news", "source_name": "Github.com", "title": "Show HN: CCG – Block merges until devs prove they read their own diff", "description": "Article URL: https://github.com/islandbytesio/commit_comprehension_gate\nComments URL: https://news.ycombinator.com/item?id=47698781\nPoints: 2\n# Comments: 0", "url": "https://github.com/islandbytesio/commit_comprehension_gate", "date": "2026-04-09", "published_at": "2026-04-09T02:49:36Z", "sentiment": { "label": "negative", "score": -0.44, "confidence": 0.44 } }, { "source": "news", "source_name": "Github.com", "title": "Show HN: Infer – Pipe friendly Agent Harness with one tool: Bash", "description": "I wanted a lightweight harness to run local models. By constraining it to a single tool (Bash) the focus can be on building the programs around it and making the program itself as close to using a Unix program as possible so that it is also easily fit into an…", "url": "https://github.com/turlockmike/infer", "date": "2026-04-08", "published_at": "2026-04-08T23:55:21Z", "sentiment": { "label": "positive", "score": 0.796, "confidence": 0.8 } }, { "source": "news", "source_name": "Gibil.dev", "title": "Show HN: Give Claude Code disposable servers to work on tasks in parallel", "description": "Just launched. Looking for first users and feedback!\n\nComments URL: https://news.ycombinator.com/item?id=47696013\nPoints: 2\n# Comments: 0", "url": "https://www.gibil.dev/", "date": "2026-04-08", "published_at": "2026-04-08T20:44:28Z", "sentiment": { "label": "positive", "score": 0.2, "confidence": 0.2 } }, { "source": "news", "source_name": "Github.com", "title": "Show HN: BAREmail ʕ·ᴥ·ʔ – minimalist Gmail client for bad WiFi", "description": "I've been frustrated one too many times by terrible airplane wifi and not being able to load Gmail or Superhuman when all I want to do is get a few simple text-only emails out the door.These clients have become pretty bloated with the assumption you've always…", "url": "https://github.com/matt-virgo/baremail", "date": "2026-04-08", "published_at": "2026-04-08T14:44:23Z", "sentiment": { "label": "negative", "score": -0.758, "confidence": 0.76 } }, { "source": "news", "source_name": "BleepingComputer", "title": "Is a $30,000 GPU Good at Password Cracking?", "description": "A $30,000 AI GPU doesn't outperform consumer GPUs at password cracking. Specops explains why attackers don't need exotic hardware to break weak passwords. [...]", "url": "https://www.bleepingcomputer.com/news/security/is-a-30-000-gpu-good-at-password-cracking/", "date": "2026-04-08", "published_at": "2026-04-08T14:00:10Z", "sentiment": { "label": "negative", "score": -0.372, "confidence": 0.37 } }, { "source": "news", "source_name": "Linuxgizmos.com", "title": "Sony AS-DT1 LiDAR Depth Sensor Now Available in Compact 29 mm Form Factor", "description": "Sony Electronics has announced availability of the AS-DT1 LiDAR depth sensor, unveiled last year. It is described as one of the smallest LiDAR sensors in its class and is designed for integration into size- and weight-constrained systems such as mobile robots…", "url": "https://linuxgizmos.com/sony-as-dt1-lidar-depth-sensor-now-available-in-compact-29-mm-form-factor/", "date": "2026-04-08", "published_at": "2026-04-08T04:31:30Z", "sentiment": { "label": "neutral", "score": 0.0, "confidence": 0.0 } }, { "source": "news", "source_name": "Thechronicle.com.gh", "title": "Introduce Modernised E-Levy To Rake In Revenue -CPS", "description": "A strong case has been made for the reintroduction of a redesigned Electronic Transfer Levy (E-Levy), as Economists and tax experts warn that Ghana’s decision to abolish key taxes risks widening fiscal deficits and undermining long-term development. The propo…", "url": "https://thechronicle.com.gh/introduce-modernised-e-levy-to-rake-in-revenue-cps/", "date": "2026-04-08", "published_at": "2026-04-08T00:45:01Z", "sentiment": { "label": "negative", "score": -0.178, "confidence": 0.18 } }, { "source": "news", "source_name": "GlobeNewswire", "title": "Rapid Growth in Cell-Free Tumor DNA Detection Market: Forecast to Reach $5.64 Billion by 2030 as Advancements in Personalized Medicine Propel Expansion", "description": "Dublin, April 07, 2026 (GLOBE NEWSWIRE) -- The \"Cell Free Tumor Deoxyribonucleic Acid (DNA) Detection Market Report 2026\" has been added to ResearchAndMarkets.com's offering.", "url": "https://www.globenewswire.com/news-release/2026/04/07/3269503/28124/en/Rapid-Growth-in-Cell-Free-Tumor-DNA-Detection-Market-Forecast-to-Reach-5-64-Billion-by-2030-as-Advancements-in-Personalized-Medicine-Propel-Expansion.html", "date": "2026-04-07", "published_at": "2026-04-07T16:23:00Z", "sentiment": { "label": "positive", "score": 0.202, "confidence": 0.2 } }, { "source": "news", "source_name": "GlobeNewswire", "title": "Molecular Tumor Board Solutions Market Outlook 2026-2030 & 2035 with Competitor Market Share Data", "description": "Key growth factors include expanding precision oncology programs, genomic data integration, and cloud deployment in healthcare, with strong potential in Asia-Pacific Key growth factors include expanding precision oncology programs, genomic data integration, a…", "url": "https://www.globenewswire.com/news-release/2026/04/07/3269500/28124/en/Molecular-Tumor-Board-Solutions-Market-Outlook-2026-2030-2035-with-Competitor-Market-Share-Data.html", "date": "2026-04-07", "published_at": "2026-04-07T16:15:00Z", "sentiment": { "label": "positive", "score": 0.832, "confidence": 0.83 } }, { "source": "news", "source_name": "NYLON", "title": "Katseye On Coachella, Conflict & 'Showing Up For Each Other'", "description": "Days before Manon's hiatus, Katseye opened up about their \"Gnarly\" rise to fame, conflict resolution, their \"iconic\" Coachella plans, and new single \"Pinky Up.\"", "url": "https://www.nylon.com/entertainment/katseye-coachella-cover-story-interview", "date": "2026-04-07", "published_at": "2026-04-07T12:22:35Z", "sentiment": { "label": "negative", "score": -0.178, "confidence": 0.18 } }, { "source": "news", "source_name": "Pypi.org", "title": "gh-ai-runner 0.1.5", "description": "Serverless AI inference via GitHub Actions — no server required", "url": "https://pypi.org/project/gh-ai-runner/0.1.5/", "date": "2026-04-07", "published_at": "2026-04-07T04:20:51Z", "sentiment": { "label": "negative", "score": -0.296, "confidence": 0.3 } }, { "source": "news", "source_name": "Thechronicle.com.gh", "title": "Deliver Value For Money Or Face Sanctions – GETFund Boss Warns Contractors", "description": "The Administrator of the Ghana Education Trust Fund (GETFund), Paul Adjei, has reaffirmed the Fund’s commitment to enforcing strict quality standards in the execution of education infrastructure projects, warning contractors to deliver value for money or face…", "url": "https://thechronicle.com.gh/deliver-value-for-money-or-face-sanctions-getfund-boss-warns-contractors/", "date": "2026-04-07", "published_at": "2026-04-07T01:09:57Z", "sentiment": { "label": "positive", "score": 0.784, "confidence": 0.78 } }, { "source": "news", "source_name": "Pypi.org", "title": "skills-forge added to PyPI", "description": "A clean-architecture toolkit for crafting, linting, packing, and sharing Claude Code skills", "url": "https://pypi.org/project/skills-forge/", "date": "2026-04-06", "published_at": "2026-04-06T20:51:34Z", "sentiment": { "label": "positive", "score": 0.421, "confidence": 0.42 } }, { "source": "news", "source_name": "Pypi.org", "title": "gh-ai-runner 0.1.3", "description": "Serverless AI inference via GitHub Actions — no server required", "url": "https://pypi.org/project/gh-ai-runner/", "date": "2026-04-06", "published_at": "2026-04-06T20:17:03Z", "sentiment": { "label": "negative", "score": -0.296, "confidence": 0.3 } }, { "source": "news", "source_name": "Github.com", "title": "Show HN: Orchestrating AI into reviewable PRs you can reason about", "description": "Article URL: https://github.com/ninthwave-sh/ninthwave\nComments URL: https://news.ycombinator.com/item?id=47662921\nPoints: 2\n# Comments: 0", "url": "https://github.com/ninthwave-sh/ninthwave", "date": "2026-04-06", "published_at": "2026-04-06T16:20:13Z", "sentiment": { "label": "neutral", "score": 0.0, "confidence": 0.0 } }, { "source": "news", "source_name": "Github.com", "title": "Show HN: A Open Source Claude Code setup to publish Research papers 10x faster", "description": "Software engineering productivity increased dramatically with AI, but research workflows still feel slow and fragmented.So I built R-stack, a Claude code setup tailor made for ML and other computational Research.You just give it your idea and R-stack will:\n• …", "url": "https://github.com/sunnnybala/Rstack", "date": "2026-04-06", "published_at": "2026-04-06T15:09:22Z", "sentiment": { "label": "positive", "score": 0.141, "confidence": 0.14 } }, { "source": "news", "source_name": "Plos.org", "title": "Role of the C-terminal modules of Klebsiella phage KP32 receptor-binding protein gp38 in protein and phage functionality", "description": "Author summary Phages are viruses that attack bacteria, and they are being studied as possible alternatives to antibiotics, which are losing their effectiveness. But one big question remains: how do phages know which bacteria to infect? In our work, we looked…", "url": "https://journals.plos.org/plospathogens/article?id=10.1371/journal.ppat.1014106", "date": "2026-04-06", "published_at": "2026-04-06T14:00:00Z", "sentiment": { "label": "negative", "score": -0.431, "confidence": 0.43 } }, { "source": "news", "source_name": "Pypi.org", "title": "geoafrica added to PyPI", "description": "A unified geospatial data SDK for Africa and the world — open data, one package.", "url": "https://pypi.org/project/geoafrica/", "date": "2026-04-06", "published_at": "2026-04-06T13:53:24Z", "sentiment": { "label": "positive", "score": 0.382, "confidence": 0.38 } }, { "source": "news", "source_name": "Internet", "title": "How LiteLLM Turned Developer Machines Into Credential Vaults for Attackers", "description": "The most active piece of enterprise infrastructure in the company is the developer workstation. That laptop is where credentials are created, tested, cached, copied, and reused across services, bots, build tools, and now local AI agents.\nIn March 2026, the Te…", "url": "https://thehackernews.com/2026/04/how-litellm-turned-developer-machines.html", "date": "2026-04-06", "published_at": "2026-04-06T11:45:00Z", "sentiment": { "label": "positive", "score": 0.075, "confidence": 0.08 } }, { "source": "news", "source_name": "Wattsupwiththat.com", "title": "Demonstrating the Reverse Greenhouse Effect in the Laboratory – PART2", "description": "Measured gas emissions show increased infrared radiation and localized cooling effects, offering experimental observations relevant to ongoing debates over greenhouse processes.", "url": "https://wattsupwiththat.com/2026/04/06/demonstrating-the-reverse-greenhouse-effect-in-the-laboratory-part2/", "date": "2026-04-06", "published_at": "2026-04-06T09:00:00Z", "sentiment": { "label": "positive", "score": 0.273, "confidence": 0.27 } }, { "source": "news", "source_name": "Pypi.org", "title": "gh-llm 0.1.13", "description": " CLI tooling for LLM-first GitHub reading and review workflows.", "url": "https://pypi.org/project/gh-llm/0.1.13/", "date": "2026-04-06", "published_at": "2026-04-06T06:55:59Z", "sentiment": { "label": "neutral", "score": 0.0, "confidence": 0.0 } }, { "source": "news", "source_name": "Pypi.org", "title": "mdarena added to PyPI", "description": "Benchmark your CLAUDE.md against your own PRs", "url": "https://pypi.org/project/mdarena/", "date": "2026-04-05", "published_at": "2026-04-05T23:26:16Z", "sentiment": { "label": "neutral", "score": 0.0, "confidence": 0.0 } }, { "source": "news", "source_name": "Github.com", "title": "Show HN: jmux – tmux-based development environment for humans and coding agents", "description": "I've been a tmux user for years. When I started running 5-10 Claude Code sessions in parallel, I tried the tools that are out there: Conductor, cmux, the GUI orchestrators. None of them felt right. They either wanted me to leave tmux entirely for a 100MB+ Ele…", "url": "https://github.com/jarredkenny/jmux", "date": "2026-04-05", "published_at": "2026-04-05T15:10:14Z", "sentiment": { "label": "negative", "score": -0.052, "confidence": 0.05 } }, { "source": "news", "source_name": "Wattsupwiththat.com", "title": "Demonstrating the Reverse Greenhouse Effect in the Laboratory – PART1", "description": "Laboratory experiments explore infrared emission of greenhouse gases under normal pressure, raising questions about atmospheric heat transfer and radiative assumptions.", "url": "https://wattsupwiththat.com/2026/04/05/demonstrating-the-reverse-greenhouse-effect-in-the-laboratory/", "date": "2026-04-05", "published_at": "2026-04-05T09:00:00Z", "sentiment": { "label": "negative", "score": -0.296, "confidence": 0.3 } }, { "source": "news", "source_name": "Pypi.org", "title": "torchtext2 added to PyPI", "description": "Add your description here", "url": "https://pypi.org/project/torchtext2/", "date": "2026-04-04", "published_at": "2026-04-04T10:48:30Z", "sentiment": { "label": "neutral", "score": 0.0, "confidence": 0.0 } }, { "source": "news", "source_name": "Github.com", "title": "Show HN: RemembrallMCP – code dependency graph for agents and memory", "description": "After watching Claude Code and Codex keep running Explore in my codebase over and over, I started to think that there must be a better way. RemembrallMCP is my attempt to fix this.RemembrallMCP gives agents two things most memory tools don't:1. Persistent Mem…", "url": "https://github.com/cdnsteve/remembrallmcp", "date": "2026-04-04", "published_at": "2026-04-04T06:39:29Z", "sentiment": { "label": "positive", "score": 0.44, "confidence": 0.44 } }, { "source": "news", "source_name": "Pypi.org", "title": "parol-pygen 0.1.0", "description": "Python parser generator/runtime consuming parol export JSON", "url": "https://pypi.org/project/parol-pygen/", "date": "2026-04-03", "published_at": "2026-04-03T14:25:06Z", "sentiment": { "label": "neutral", "score": 0.0, "confidence": 0.0 } }, { "source": "news", "source_name": "Github.com", "title": "Show HN: Zumly – a library for building zooming user interfaces", "description": "Article URL: https://github.com/zumerlab/zumly\nComments URL: https://news.ycombinator.com/item?id=47625640\nPoints: 1\n# Comments: 1", "url": "https://github.com/zumerlab/zumly", "date": "2026-04-03", "published_at": "2026-04-03T11:53:42Z", "sentiment": { "label": "neutral", "score": 0.0, "confidence": 0.0 } }, { "source": "news", "source_name": "Thechronicle.com.gh", "title": "Three Remanded Over Alleged Land cruiser Theft in Tarkwa", "description": "The Circuit Court in Tarkwa, presided over by Her Honour Bernice Mensimah Akoh, has remanded three persons into custody for their alleged involvement in a vehicle theft syndicate operating in the area. The accused persons are Kojo Amponsah, also known as “Kam…", "url": "https://thechronicle.com.gh/three-remanded-over-alleged-land-cruiser-theft-in-tarkwa/", "date": "2026-04-03", "published_at": "2026-04-03T11:24:01Z", "sentiment": { "label": "positive", "score": 0.361, "confidence": 0.36 } }, { "source": "news", "source_name": "Thechronicle.com.gh", "title": "Dispatch Rider Jailed 10 Years for Robbing Diplomat’s Secretary", "description": "The Circuit Court at Dansoman has sentenced a 24-year-old dispatch rider to 10 years’ imprisonment for robbing the Secretary to the Namibian High Commissioner in Ghana. The convict, Daniel Asiuebi, pleaded guilty simpliciter to two counts of robbery and causi…", "url": "https://thechronicle.com.gh/dispatch-rider-jailed-10-years-for-robbing-diplomats-secretary/", "date": "2026-04-03", "published_at": "2026-04-03T11:21:38Z", "sentiment": { "label": "negative", "score": -0.727, "confidence": 0.73 } }, { "source": "news", "source_name": "Seclists.org", "title": "Re: [vim-security] Vim tabpanel modeline escape affects Vim", "description": "Posted by Salvatore Bonaccorso on Apr 03Hi,\n\nAccording to https://www.cve.org/CVERecord?id=CVE-2026-34714 the\nassigner is MITRE CNA itself.\n\nRegards,\nSalvatore", "url": "https://seclists.org/oss-sec/2026/q2/20", "date": "2026-04-03", "published_at": "2026-04-03T09:51:48Z", "sentiment": { "label": "positive", "score": 0.178, "confidence": 0.18 } }, { "source": "news", "source_name": "Bulinews.com", "title": "Former Germany coach Joachim Löw linked with World Cup job", "description": "Joachim Löw, who won the World Cup with Germany in 2014, is said to be close to a return to coaching.Citing “multiple sources,” Ghanasoccernet.com reports that Löw is close to being appointed Gh...", "url": "https://bulinews.com/former-germany-coach-joachim-low-linked-world-cup-job", "date": "2026-04-03", "published_at": "2026-04-03T09:08:00Z", "sentiment": { "label": "positive", "score": 0.572, "confidence": 0.57 } }, { "source": "news", "source_name": "Pypi.org", "title": "release-cli added to PyPI", "description": "AI-assisted CLI release manager powered by Backboard", "url": "https://pypi.org/project/release-cli/", "date": "2026-04-03", "published_at": "2026-04-03T00:11:17Z", "sentiment": { "label": "neutral", "score": 0.0, "confidence": 0.0 } }, { "source": "news", "source_name": "Pypi.org", "title": "memex-oss added to PyPI", "description": "Institutional knowledge extraction for engineering teams", "url": "https://pypi.org/project/memex-oss/", "date": "2026-04-02", "published_at": "2026-04-02T16:25:08Z", "sentiment": { "label": "neutral", "score": 0.0, "confidence": 0.0 } }, { "source": "news", "source_name": "TechRadar", "title": "5 popular OpenClaw integrations that will level up your productivity", "description": "A practical look at five of the most popular OpenClaw integrations, covering messaging, productivity, developer tools, and smart home control.", "url": "https://www.techradar.com/pro/5-popular-openclaw-integrations-that-will-level-up-your-productivity", "date": "2026-04-02", "published_at": "2026-04-02T14:43:31Z", "sentiment": { "label": "positive", "score": 0.822, "confidence": 0.82 } }, { "source": "news", "source_name": "Plos.org", "title": "Football (Soccer) refereeing and cardiovascular health: A scoping review", "description": "Background Physical and psychological stress can precipitate Acute Coronary Syndrome (ACS) events. Football (soccer) is a popular sport globally, with referees covering significant distances, often at high-intensity during a match, and facing potentially inte…", "url": "https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0346360", "date": "2026-04-02", "published_at": "2026-04-02T14:00:00Z", "sentiment": { "label": "positive", "score": 0.202, "confidence": 0.2 } }, { "source": "news", "source_name": "Plos.org", "title": "Availability and affordability of essential medicines for non-communicable disease management in primary healthcare: Evidence from three municipalities in Ghana", "description": "Background Non-communicable diseases (NCDs) cause 74% of global deaths, disproportionately affecting LMICs like Ghana. Chronic treatment remains hindered by medicine shortages and high costs, consuming over 50% of the minimum wage incomes. Despite Ghana’s NCD…", "url": "https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0346140", "date": "2026-04-02", "published_at": "2026-04-02T14:00:00Z", "sentiment": { "label": "positive", "score": 0.226, "confidence": 0.23 } }, { "source": "news", "source_name": "Plos.org", "title": "Effects of a native avian predator (weka; Gallirallus australis) and colony density on breeding success of a burrow-nesting seabird (tītī; Ardenna grisea)", "description": "As island ecosystems are restored, native predators are recovering and re-establishing interactions with their prey. However, compared with widely-publicised impacts of invasive predators, little is known about the dynamics and stability of native predator-pr…", "url": "https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0346357", "date": "2026-04-02", "published_at": "2026-04-02T14:00:00Z", "sentiment": { "label": "positive", "score": 0.802, "confidence": 0.8 } }, { "source": "news", "source_name": "YEN.COM.GH", "title": "Former Health Minister Dr Bernard Okoe-Boye Summoned Before PAC", "description": "The former Health Minister, Dr Bernard Okoe-Boye, has been summoned by PAC over GH¢20 million in mobilisation funds for the Parliamentary Hospital.", "url": "https://yen.com.gh/politics/302253-former-health-minister-dr-bernard-okoe-boye-summoned-pac/", "date": "2026-04-02", "published_at": "2026-04-02T12:36:49Z", "sentiment": { "label": "neutral", "score": 0.0, "confidence": 0.0 } } ] } }